[
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01075100",
        "briefTitle": "Ixabepilone + Carboplatin Metastatic Breast Cancer",
        "officialTitle": "Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2010-01"
        },
        "completionDateStruct": {
          "date": "2013-06"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "US Oncology Research"
        },
        "collaborators": [
          {
            "name": "Bristol-Myers Squibb"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Metastatic Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 103,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "55.0",
                        "spread": "9.0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "56.7",
                        "spread": "10.6"
                      },
                      {
                        "groupId": "BG002",
                        "value": "55.9",
                        "spread": "9.9"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "49"
                      },
                      {
                        "groupId": "BG001",
                        "value": "54"
                      },
                      {
                        "groupId": "BG002",
                        "value": "103"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Caucasian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "33"
                      },
                      {
                        "groupId": "BG001",
                        "value": "39"
                      },
                      {
                        "groupId": "BG002",
                        "value": "72"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hispanic",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hawaiian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Black",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "14"
                      },
                      {
                        "groupId": "BG001",
                        "value": "10"
                      },
                      {
                        "groupId": "BG002",
                        "value": "24"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Asian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "49"
                      },
                      {
                        "groupId": "BG001",
                        "value": "54"
                      },
                      {
                        "groupId": "BG002",
                        "value": "103"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Objective Response Rate (ORR)",
            "description": "Evaluate the objective response rate calculated as CR+ PR in the population evaluable for response, as well as the 2 subgroups (hormone receptor positive \\[ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-\\]) and ER-/PR-HER2-, separately).\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
            "populationDescription": "Evaluable population",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "24 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "46"
                  },
                  {
                    "groupId": "OG001",
                    "value": "53"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "30.4",
                        "lowerLimit": "17.7",
                        "upperLimit": "45.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "34",
                        "lowerLimit": "21.5",
                        "upperLimit": "48.3"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Clinical Benefit Rate (CBR)",
            "description": "Clinical benefit rate (CBR) defined as objective response rate (ORR, CR + PR) + SD \\>= 6 months",
            "populationDescription": "Evaluable population",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "24 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "46"
                  },
                  {
                    "groupId": "OG001",
                    "value": "53"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "41.3",
                        "lowerLimit": "27.0",
                        "upperLimit": "56.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "56.6",
                        "lowerLimit": "42.3",
                        "upperLimit": "70.2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Progression-free Survival (PFS)",
            "description": "PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",
            "populationDescription": "ITT population",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "months",
            "timeFrame": "24 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "49"
                  },
                  {
                    "groupId": "OG001",
                    "value": "54"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.6",
                        "lowerLimit": "4.3",
                        "upperLimit": "8.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.6",
                        "lowerLimit": "4.2",
                        "upperLimit": "9.8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Overall Survival (OS)",
            "description": "OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.",
            "populationDescription": "ITT population",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "months",
            "timeFrame": "24 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who receive Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "49"
                  },
                  {
                    "groupId": "OG001",
                    "value": "54"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.5",
                        "lowerLimit": "10.2",
                        "upperLimit": "14.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "17.9",
                        "lowerLimit": "14.4",
                        "upperLimit": "22.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Response",
            "description": "For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.",
            "populationDescription": "Patients who achieve a major objective response (CR or PR).",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Full Range",
            "unitOfMeasure": "months",
            "timeFrame": "24 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who receive Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "14"
                  },
                  {
                    "groupId": "OG001",
                    "value": "18"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.27",
                        "lowerLimit": "0.92",
                        "upperLimit": "3.98"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.60",
                        "lowerLimit": "1.12",
                        "upperLimit": "8.95"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Duration of Response",
            "description": "The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.",
            "populationDescription": "Patients who achieved CR or PR.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Full Range",
            "unitOfMeasure": "months",
            "timeFrame": "30 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Triple Negative",
                "description": "ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              },
              {
                "id": "OG001",
                "title": "HR Positive",
                "description": "ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "14"
                  },
                  {
                    "groupId": "OG001",
                    "value": "18"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.68",
                        "lowerLimit": "2.43",
                        "upperLimit": "20.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.92",
                        "lowerLimit": "1.84",
                        "upperLimit": "25.6"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01276938",
        "briefTitle": "Exclusive Intraoperative Radiation Therapy for Breast Cancer",
        "officialTitle": "Tolerance Evaluation of Exclusive Intraoperative Radiation Therapy at Different Doses for Breast Cancer Conservative Treatment"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2009-04"
        },
        "completionDateStruct": {
          "date": "2011-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms",
          "Toxicity"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2",
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 40,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Italy"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03372902",
        "briefTitle": "Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening",
        "officialTitle": "MSK Discovery Study: Use of cfNA To Distinguish Between Benign and Malignant BI-RADS 4 Radiographic Lesions"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2017-12-07"
        },
        "completionDateStruct": {
          "date": "2025-03-12"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Memorial Sloan Kettering Cancer Center"
        },
        "collaborators": [
          {
            "name": "GRAIL, Inc."
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Breast Benign"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 628,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02897375",
        "briefTitle": "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors",
        "officialTitle": "A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2016-10-24"
        },
        "completionDateStruct": {
          "date": "2021-10-15"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Emory University"
        },
        "collaborators": [
          {
            "name": "Pfizer"
          },
          {
            "name": "National Institutes of Health (NIH)"
          },
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Solid Neoplasm",
          "Stage III Pancreatic Cancer",
          "Stage IIIA Breast Cancer",
          "Stage IIIA Non-Small Cell Lung Cancer",
          "Stage IIIB Breast Cancer",
          "Stage IIIB Non-Small Cell Lung Cancer",
          "Stage IIIC Breast Cancer",
          "Stage IV Breast Cancer",
          "Stage IV Non-Small Cell Lung Cancer",
          "Stage IVA Pancreatic Cancer",
          "Stage IVB Pancreatic Cancer",
          "Sarcoma",
          "Colorectal Cancer",
          "Head and Neck Cancer",
          "Cancer of Unknown Primary",
          "Bladder Cancer",
          "Ovarian Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 71,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03912948",
        "briefTitle": "Chronic Pain and Minor Breast Cancer Surgery",
        "officialTitle": "Prospective Cohort Study Assessing Chronic Pain in Patients With Thoracic Blocks Following Minor Surgery for Breast Cancer."
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2019-04-01"
        },
        "completionDateStruct": {
          "date": "2019-12-31"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Institut Claudius Regaud"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Surgery",
          "Breast Cancer",
          "Pain, Postoperative",
          "Pain, Chronic"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 205,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04117815",
        "briefTitle": "Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy",
        "officialTitle": "Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2018-05-18"
        },
        "completionDateStruct": {
          "date": "2021-02-28"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Medical University Innsbruck"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer Female",
          "Alopecia"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 128,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Austria"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00005590",
        "briefTitle": "Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma",
        "officialTitle": "A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "1999-08"
        },
        "completionDateStruct": {
          "date": "2005-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Cancer Research Campaign Clinical Trials Centre"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Brain and Central Nervous System Tumors",
          "Breast Cancer",
          "Extragonadal Germ Cell Tumor",
          "Infection",
          "Lung Cancer",
          "Lymphoma",
          "Ovarian Cancer",
          "Small Intestine Cancer",
          "Testicular Germ Cell Tumor",
          "Unspecified Adult Solid Tumor, Protocol Specific"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United Kingdom"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01317108",
        "briefTitle": "Prognostic and Predictive Impact of uPA/PAI-1",
        "officialTitle": "Adjuvant Chemotherapy in Node-negative Breast Cancer: Chemo N0"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "1993-06"
        },
        "completionDateStruct": {
          "date": "2008-12"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Universit\u00e4tsklinikum Hamburg-Eppendorf"
        },
        "collaborators": [
          {
            "name": "Technical University of Munich"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 689,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {}
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02719691",
        "briefTitle": "Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer",
        "officialTitle": "A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2016-05-13"
        },
        "completionDateStruct": {
          "date": "2020-03-18"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Colorado, Denver"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Metastatic Breast Cancer",
          "Solid Tumors"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 47,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Categorical",
            "populationDescription": "2 subjects were not analyzed as they were withdrawn from the study.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "calculatePct": false,
            "classes": [
              {
                "categories": [
                  {
                    "title": "<=18 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "0"
                      },
                      {
                        "groupId": "BG005",
                        "value": "0"
                      },
                      {
                        "groupId": "BG006",
                        "value": "0"
                      },
                      {
                        "groupId": "BG007",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      },
                      {
                        "groupId": "BG003",
                        "value": "1"
                      },
                      {
                        "groupId": "BG004",
                        "value": "6"
                      },
                      {
                        "groupId": "BG005",
                        "value": "4"
                      },
                      {
                        "groupId": "BG006",
                        "value": "9"
                      },
                      {
                        "groupId": "BG007",
                        "value": "26"
                      }
                    ]
                  },
                  {
                    "title": ">=65 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      },
                      {
                        "groupId": "BG003",
                        "value": "1"
                      },
                      {
                        "groupId": "BG004",
                        "value": "4"
                      },
                      {
                        "groupId": "BG005",
                        "value": "5"
                      },
                      {
                        "groupId": "BG006",
                        "value": "2"
                      },
                      {
                        "groupId": "BG007",
                        "value": "19"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Age, Continuous",
            "populationDescription": "2 subjects were not analyzed as they were withdrawn from the study.",
            "paramType": "MEAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "63.7",
                        "lowerLimit": "60",
                        "upperLimit": "68"
                      },
                      {
                        "groupId": "BG001",
                        "value": "64.8",
                        "lowerLimit": "59",
                        "upperLimit": "69"
                      },
                      {
                        "groupId": "BG002",
                        "value": "64.5",
                        "lowerLimit": "48",
                        "upperLimit": "76"
                      },
                      {
                        "groupId": "BG003",
                        "value": "65.5",
                        "lowerLimit": "57",
                        "upperLimit": "74"
                      },
                      {
                        "groupId": "BG004",
                        "value": "61.7",
                        "lowerLimit": "51",
                        "upperLimit": "72"
                      },
                      {
                        "groupId": "BG005",
                        "value": "61.9",
                        "lowerLimit": "40",
                        "upperLimit": "75"
                      },
                      {
                        "groupId": "BG006",
                        "value": "56.9",
                        "lowerLimit": "39",
                        "upperLimit": "74"
                      },
                      {
                        "groupId": "BG007",
                        "value": "61.4",
                        "lowerLimit": "39",
                        "upperLimit": "76"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "populationDescription": "2 subjects were not analyzed as they were withdrawn from the study.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "5"
                      },
                      {
                        "groupId": "BG003",
                        "value": "2"
                      },
                      {
                        "groupId": "BG004",
                        "value": "8"
                      },
                      {
                        "groupId": "BG005",
                        "value": "6"
                      },
                      {
                        "groupId": "BG006",
                        "value": "2"
                      },
                      {
                        "groupId": "BG007",
                        "value": "29"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "2"
                      },
                      {
                        "groupId": "BG005",
                        "value": "3"
                      },
                      {
                        "groupId": "BG006",
                        "value": "9"
                      },
                      {
                        "groupId": "BG007",
                        "value": "16"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "populationDescription": "2 subjects were not analyzed as they were withdrawn from the study.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "1"
                      },
                      {
                        "groupId": "BG005",
                        "value": "1"
                      },
                      {
                        "groupId": "BG006",
                        "value": "3"
                      },
                      {
                        "groupId": "BG007",
                        "value": "6"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      },
                      {
                        "groupId": "BG003",
                        "value": "2"
                      },
                      {
                        "groupId": "BG004",
                        "value": "9"
                      },
                      {
                        "groupId": "BG005",
                        "value": "8"
                      },
                      {
                        "groupId": "BG006",
                        "value": "8"
                      },
                      {
                        "groupId": "BG007",
                        "value": "38"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "0"
                      },
                      {
                        "groupId": "BG005",
                        "value": "0"
                      },
                      {
                        "groupId": "BG006",
                        "value": "0"
                      },
                      {
                        "groupId": "BG007",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "populationDescription": "2 subjects were not analyzed as they were withdrawn from the study.",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "6"
                      },
                      {
                        "groupId": "BG003",
                        "value": "2"
                      },
                      {
                        "groupId": "BG004",
                        "value": "10"
                      },
                      {
                        "groupId": "BG005",
                        "value": "9"
                      },
                      {
                        "groupId": "BG006",
                        "value": "11"
                      },
                      {
                        "groupId": "BG007",
                        "value": "45"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03",
            "description": "The maximum tolerated dose (MTD) will be defined as the highest dose level evaluated in which 0 or 1 patient out of 6 patients experiences dose limiting toxicity (DLT) in the combination of MLN0128 and Alisertib. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "mg",
            "timeFrame": "Up to 28 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Dose-Escalation of Alisertib and MLN0128",
                "description": "This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.\n\nAlisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.\n\nMLN0128: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "15"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "alisertib",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "30"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "TAK228",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "The Safety Profile and Tolerability of the Combination of MLN0128 and Alisertib in Adult Patients With Advanced Solid Tumors.",
            "description": "Adverse events will be tabulated by type and grade according to the NCI CTCAE v.4.03. Please see adverse events section.",
            "populationDescription": "Number of participants with at least one adverse event.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "At least 30 days after the last dose of MLN0128 or alisertib",
            "groups": [
              {
                "id": "OG000",
                "title": "Dose Level 1: Alisertib 30 mg/MLN0128 1 mg",
                "description": "This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.\n\nAlisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.\n\nMLN0128: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study."
              },
              {
                "id": "OG001",
                "title": "Dose Level 2: Alisertib 30 mg/MLN0128 2 mg",
                "description": "This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.\n\nAlisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
              },
              {
                "id": "OG002",
                "title": "Dose Level 3: Alisertib 40 mg/MLN0128 2 mg",
                "description": "This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.\n\nAlisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
              },
              {
                "id": "OG003",
                "title": "Dose Level 4: Alisertib 40 mg/MLN0128 3 mg",
                "description": "This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.\n\nAlisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
              },
              {
                "id": "OG004",
                "title": "Dose-Expansion of Alisertib and MLN0128: Group 1",
                "description": "This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21."
              },
              {
                "id": "OG005",
                "title": "Dose Expansion of Alisertib and MLN0128: Group 2",
                "description": "This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21."
              },
              {
                "id": "OG006",
                "title": "Pancreatic Cancer Cohort",
                "description": "This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "3"
                  },
                  {
                    "groupId": "OG001",
                    "value": "4"
                  },
                  {
                    "groupId": "OG002",
                    "value": "7"
                  },
                  {
                    "groupId": "OG003",
                    "value": "2"
                  },
                  {
                    "groupId": "OG004",
                    "value": "10"
                  },
                  {
                    "groupId": "OG005",
                    "value": "10"
                  },
                  {
                    "groupId": "OG006",
                    "value": "11"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4"
                      },
                      {
                        "groupId": "OG002",
                        "value": "7"
                      },
                      {
                        "groupId": "OG003",
                        "value": "2"
                      },
                      {
                        "groupId": "OG004",
                        "value": "10"
                      },
                      {
                        "groupId": "OG005",
                        "value": "10"
                      },
                      {
                        "groupId": "OG006",
                        "value": "11"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00972413",
        "briefTitle": "Cone Beam Computed Tomography for Breast Imaging",
        "officialTitle": "Cone Beam Computed Tomography for Breast Imaging and IV Contrast Enhanced Cone Beam Computed Tomography Breast Imaging"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2008-06"
        },
        "completionDateStruct": {
          "date": "2012-05"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Koning Corporation"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 104,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04105582",
        "briefTitle": "Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells",
        "officialTitle": "Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple Negative Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2019-08-01"
        },
        "completionDateStruct": {
          "date": "2022-02-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Universidad Nacional de Colombia"
        },
        "collaborators": [
          {
            "name": "Fundaci\u00f3n Salud de los Andes"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Triple Negative Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 5,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Colombia"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04465097",
        "briefTitle": "Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer",
        "officialTitle": "Neoadjuvant Tucidinostat and Exemestane in Estrogen Receptor-Positive Early Breast Cancer \uff08NeoTEE\uff09"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-07-08"
        },
        "completionDateStruct": {
          "date": "2023-10-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "First Affiliated Hospital, Sun Yat-Sen University"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 30,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "China"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00174655",
        "briefTitle": "BIG 02/98 Docetaxel - Breast Cancer",
        "officialTitle": "An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients."
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "1998-06"
        },
        "completionDateStruct": {
          "date": "2011-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Sanofi"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 2887,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Australia"
          },
          {
            "country": "Austria"
          },
          {
            "country": "Belgium"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Chile"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Denmark"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Ireland"
          },
          {
            "country": "Israel"
          },
          {
            "country": "Italy"
          },
          {
            "country": "New Zealand"
          },
          {
            "country": "Portugal"
          },
          {
            "country": "Slovakia"
          },
          {
            "country": "Slovenia"
          },
          {
            "country": "South Africa"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Switzerland"
          },
          {
            "country": "United Kingdom"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00369655",
        "briefTitle": "VEGF Trap in Treating Patients With Metastatic Breast Cancer",
        "officialTitle": "Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2007-01"
        },
        "completionDateStruct": {
          "date": "2011-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "National Cancer Institute (NCI)"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Metastatic Breast Cancer",
          "Recurrent Breast Cancer",
          "Stage IV Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 21,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEDIAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "58",
                        "lowerLimit": "34",
                        "upperLimit": "75"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex/Gender, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Female",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "21"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "21"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "ECOG Performance Score",
            "description": "The Eastern Cooperative Oncology Group (ECOG) score classified patients according to their functional impairment. Scores range from 0 (fully active) to 5 (death).",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "0-Fully active",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "14"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "1-Ambulatory, restricted strenuous activity",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Cell type",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Infiltrating ductal",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Infiltrating lobular",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Comedo",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Inflammatory",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Infiltrating ductal and comedo",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Missing",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Dominant Disease",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Visceral",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "15"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Nonvisceral",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Visceral Disease Site",
            "description": "The presented results are for the 15 participants with visceral disease. The same participant may report more than one disease site.",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Liver",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Lung",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Abodomen",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Estrogen Receptor (ER) Result",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Positive",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Negative",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Progesterone Receptor (PR) Result",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Positive",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Negative",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Human epidermal growth factor receptor 2 (HER2) Result",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Positive",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Negative",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "14"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "HER2 testing not done",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Previous (Neo) Adjuvant Chemotherapy",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Yes",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "13"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Number of Previous Chemotherapy Regimens",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "0",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "1",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "11"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "2",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Previous Hormonal Therapy",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Yes",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Previous Trastuzumab",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Yes",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Prior Anthracyclines",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Yes",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "15"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Prior Taxanes",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Yes",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "19"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Proportion of Patients With Confirmed Tumor Response",
            "description": "Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart.",
            "populationDescription": "All participants who have met the eligibility criteria, who have signed a consent form and have begun treatment were evaluable for response.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "Up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "21"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Confirmed tumor partial response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No Confirmed reponse",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "20"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Proportion of Patients Receiving Vascular Endothelial Growth Factor (VEGF) Trap With 6-month Progression-free Survival",
            "description": "The 6-month progression free survival rate was defined as the proportion of efficacy-evaluable patients on study treatment and progression-free 6 months from registration. Patients who died without documentation of progression will be considered to have progressed on the date of their death.",
            "populationDescription": "All participants who have met the eligibility criteria, who have signed a consent form and have begun treatment were evaluable for response.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "6 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "21"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Progression Free Survival",
            "description": "Progression-free survival was defined as the number of months from registration to the date of disease progression or death, with patients who died without documentation of progression being considered to have progressed on the date of their death.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Time from registration to disease progression or death (up to 5 years)",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "21"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.7",
                        "lowerLimit": "1.8",
                        "upperLimit": "5.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Overall Survival",
            "description": "Overall survival time was defined as the number of months from registration to the date of death or last follow-up",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Time from registration to death or last follow up (up to 5 years)",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "21"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.7",
                        "lowerLimit": "6.7",
                        "upperLimit": "31.1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Median Duration of Response",
            "description": "Duration of response was defined as for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a complete response or partial response to the date progression is documented.",
            "populationDescription": "Analysis population included only patients who have achieved a confirmed tumor response. The duration of response of 4.6 months is reported from one patient.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "1"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.6",
                        "lowerLimit": "4.6",
                        "upperLimit": "4.6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participant With Previous Treatment of Anti-HER2 With Cardiac Events",
            "populationDescription": "All participants who have received previous treatment with anti-HER2.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "Up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment (Ziv-afibercept)",
                "description": "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "5"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04750889",
        "briefTitle": "Breast Localization: RFID Tags vs Wire Localization",
        "officialTitle": "RFID Trial: Localization of Non-palpable Breast Lesions Using Radiofrequency Identification Tags or Wire"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2021-05-15"
        },
        "completionDateStruct": {
          "date": "2023-04-24"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Centre Jean Perrin"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasm Female"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 80,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03822468",
        "briefTitle": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",
        "officialTitle": "A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2019-06-11"
        },
        "completionDateStruct": {
          "date": "2024-08-30"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Novartis Pharmaceuticals"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 376,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "Argentina"
          },
          {
            "country": "Austria"
          },
          {
            "country": "Austria"
          },
          {
            "country": "Austria"
          },
          {
            "country": "Austria"
          },
          {
            "country": "Belgium"
          },
          {
            "country": "Belgium"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Bulgaria"
          },
          {
            "country": "Bulgaria"
          },
          {
            "country": "Bulgaria"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Costa Rica"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Finland"
          },
          {
            "country": "Finland"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "Jordan"
          },
          {
            "country": "Lithuania"
          },
          {
            "country": "Lithuania"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Portugal"
          },
          {
            "country": "Portugal"
          },
          {
            "country": "Portugal"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "South Africa"
          },
          {
            "country": "South Africa"
          },
          {
            "country": "South Africa"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "58.7",
                        "spread": "12.96"
                      },
                      {
                        "groupId": "BG001",
                        "value": "57.0",
                        "spread": "12.37"
                      },
                      {
                        "groupId": "BG002",
                        "value": "57.9",
                        "spread": "12.68"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "188"
                      },
                      {
                        "groupId": "BG001",
                        "value": "188"
                      },
                      {
                        "groupId": "BG002",
                        "value": "376"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Caucasian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "147"
                      },
                      {
                        "groupId": "BG001",
                        "value": "143"
                      },
                      {
                        "groupId": "BG002",
                        "value": "290"
                      }
                    ]
                  },
                  {
                    "title": "Native American or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "14"
                      },
                      {
                        "groupId": "BG001",
                        "value": "10"
                      },
                      {
                        "groupId": "BG002",
                        "value": "24"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "13"
                      },
                      {
                        "groupId": "BG001",
                        "value": "9"
                      },
                      {
                        "groupId": "BG002",
                        "value": "22"
                      }
                    ]
                  },
                  {
                    "title": "Black",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      },
                      {
                        "groupId": "BG001",
                        "value": "12"
                      },
                      {
                        "groupId": "BG002",
                        "value": "17"
                      }
                    ]
                  },
                  {
                    "title": "Other",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "5"
                      }
                    ]
                  },
                  {
                    "title": "Unknown",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "8"
                      },
                      {
                        "groupId": "BG001",
                        "value": "10"
                      },
                      {
                        "groupId": "BG002",
                        "value": "18"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Overall Response Rate (ORR)",
            "description": "ORR defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by local investigators according to RECIST 1.1.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.",
            "populationDescription": "The Full Analysis Set (FAS) including all randomized participants",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "Up to 23.8 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "188"
                  },
                  {
                    "groupId": "OG001",
                    "value": "188"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "41.5",
                        "lowerLimit": "34.4",
                        "upperLimit": "48.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "45.3",
                        "lowerLimit": "38.1",
                        "upperLimit": "52.6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in QTc (With Fridericia's Correction) at Cycle 1 Day 15 (at 2 Hours Post-dose)",
            "description": "Electrocardiogram (ECG) data was collected via 12-lead digital ECG machines. Change from baseline in the QT interval (a segment of the ECG that reflects the time it takes for the heart to repolarize after each heartbeat) was corrected for heart rate using Fridericia's formula (\u0394QTcF).",
            "populationDescription": "Participants who received at least one dose of study treatment and had available QT assessments conducted at both baseline and Cycle 1 Day 15 (2 hours post-dose)",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "milliseconds",
            "timeFrame": "Baseline and Cycle 1 Day 15 at 2 hours post-dose. Cycle = 28 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "174"
                  },
                  {
                    "groupId": "OG001",
                    "value": "175"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.5",
                        "spread": "12.91"
                      },
                      {
                        "groupId": "OG001",
                        "value": "19.7",
                        "spread": "18.50"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Progression-free Survival (PFS)",
            "description": "Progression free survival (PFS) was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. PFS was censored if no PFS event was observed. The censoring date was the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression. PFS was assessed via a local radiology assessment as well as Blinded Independent Review Committee (BIRC) according to RECIST 1.1.",
            "populationDescription": "The Full Analysis Set (FAS) including all randomized participants",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Full Range",
            "unitOfMeasure": "Months",
            "timeFrame": "Up to approximately 60 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "188"
                  },
                  {
                    "groupId": "OG001",
                    "value": "188"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "26.9",
                        "lowerLimit": "20.3",
                        "upperLimit": "30.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "25.1",
                        "lowerLimit": "19.4",
                        "upperLimit": "33.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Clinical Benefit Rate (CBR)",
            "description": "Clinical benefit rate (CBR) was defined as the proportion of patients with a best overall response of complete response (CR), or partial response (PR), or an overall response of stable disease (SD), lasting for at least 24 weeks. CR, PR, and SD were defined as per local review as well as Blinded Independent Review Committee (BIRC) according to RECIST 1.1. A patient was considered to have SD for 24 weeks or longer if a SD response was recorded at 24-1=23 weeks or later from randomization, allowing for the \u00b11 week visit window for tumor assessments.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.\n\nSD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.",
            "populationDescription": "The Full Analysis Set (FAS) including all randomized participants",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Up to approximately 60 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "188"
                  },
                  {
                    "groupId": "OG001",
                    "value": "188"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "142"
                      },
                      {
                        "groupId": "OG001",
                        "value": "133"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Response (TTR)",
            "description": "Time to response (TTR) was defined as the time from the date of randomization to the first documented response of either complete response (CR) or partial response (PR), which had to be subsequently confirmed (although the date of initial response was used, not the date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.",
            "populationDescription": "Full Analysis Set (FAS) - Only responders included",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Up to approximately 60 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "90"
                  },
                  {
                    "groupId": "OG001",
                    "value": "103"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13.1",
                        "lowerLimit": "7.4",
                        "upperLimit": "NA",
                        "comment": "NA: Not estimable due to insufficient number of participants with events"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.0",
                        "lowerLimit": "5.6",
                        "upperLimit": "16.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Duration of Response (DOR)",
            "description": "Duration of response (DOR) only applied to patients whose best overall response was complete response (CR) or partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progression or death due to underlying cancer. Patients continuing without progression or death due to underlying cancer were censored at the date of their last adequate tumor assessment.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.",
            "populationDescription": "Full Analysis Set (FAS) - Only responders included",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Up to approximately 60 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "90"
                  },
                  {
                    "groupId": "OG001",
                    "value": "103"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "26.5",
                        "lowerLimit": "16.8",
                        "upperLimit": "NA",
                        "comment": "NA: Not estimable due to insufficient number of participants with events"
                      },
                      {
                        "groupId": "OG001",
                        "value": "28.8",
                        "lowerLimit": "22.6",
                        "upperLimit": "NA",
                        "comment": "NA: Not estimable due to insufficient number of participants with events"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Pharmacokinetics (PK) of Ribociclib: Maximum Observed Plasma Concentration (Cmax)",
            "description": "PK parameters were calculated by non-compartmental analysis. Cmax is the maximum observed plasma drug concentration after single dose administration.",
            "populationDescription": "Participants who provided an evaluable PK parameter (Cmax) and received at least 10 consecutive daily ribociclib doses of 400 mg or 600 mg immediately prior to and on the PK collection day",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "nanogram / milliliter (ng / mL)",
            "timeFrame": "Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "20"
                  },
                  {
                    "groupId": "OG001",
                    "value": "16"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1240",
                        "spread": "739"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1740",
                        "spread": "918"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "PK of Ribociclib: Time to Reach Observed Maximum Concentration (Tmax)",
            "description": "PK parameters were calculated by non-compartmental analysis. Tmax is the time to reach maximum observed plasma concentration. Actual recorded sampling times were considered for the calculations.",
            "populationDescription": "Participants who provided an evaluable PK parameter (Tmax) and received at least 10 consecutive daily ribociclib doses of 400 mg or 600 mg immediately prior to and on the PK collection day",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Full Range",
            "unitOfMeasure": "hours (h)",
            "timeFrame": "Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "20"
                  },
                  {
                    "groupId": "OG001",
                    "value": "16"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.08",
                        "lowerLimit": "1.83",
                        "upperLimit": "4.38"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.00",
                        "lowerLimit": "1.83",
                        "upperLimit": "23.8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "PK of Ribociclib: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24)",
            "description": "PK parameters were calculated by non-compartmental analysis. AUC0-24 is the area under the plasma concentration-time curve from 0 to 24 hours",
            "populationDescription": "Participants who provided an evaluable PK parameter (AUC0-24) and received at least 10 consecutive daily ribociclib doses of 400 mg or 600 mg immediately prior to and on the PK collection day",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "ng x h / mL",
            "timeFrame": "Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Ribociclib 400 mg",
                "description": "Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)"
              },
              {
                "id": "OG001",
                "title": "Ribociclib 600 mg",
                "description": "Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "17"
                  },
                  {
                    "groupId": "OG001",
                    "value": "13"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "18700",
                        "spread": "11600"
                      },
                      {
                        "groupId": "OG001",
                        "value": "31600",
                        "spread": "14300"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00258050",
        "briefTitle": "To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients",
        "officialTitle": "A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2005-11-21"
        },
        "completionDateStruct": {
          "date": "2007-02-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "GlaxoSmithKline"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Neoplasms, Breast"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 24,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01115374",
        "briefTitle": "Lymphedema Therapy With Sound Wave Lymphatic Drainage",
        "officialTitle": "Efficacy of Low Frequency Sound Waves in the Treatment of Breast Cancer Related Lymphedema: a Cross-over Randomized Trial"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2008-05"
        },
        "completionDateStruct": {
          "date": "2009-07"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Fundacion IMIM"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Lymphedema"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 34,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Spain"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04829643",
        "briefTitle": "Axillary Staging in Early Breast Cancer: SNB vs PET/MRI",
        "officialTitle": "Targeting the Future of Axillary Staging in Early Breast Cancer: A Comparative Study: Sentinel Node Biopsy vs PET/MRI"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-06-01"
        },
        "completionDateStruct": {
          "date": "2024-10-30"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "IRCCS San Raffaele"
        },
        "collaborators": [
          {
            "name": "IBFM- Consiglio Nazionale delle Ricerche"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Sentinel Lymph Node",
          "Early-stage Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 246,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Italy"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01271725",
        "briefTitle": "LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures",
        "officialTitle": "LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2011-05-24"
        },
        "completionDateStruct": {
          "date": "2017-03-13"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Boehringer Ingelheim"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 74,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Hong Kong"
          },
          {
            "country": "Hong Kong"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "description": "Age at the time of signing informed consent form is presented.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "51.3",
                        "spread": "10.6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "description": "Number of subjects is categorized as Male or Female.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "74"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "description": "Ethnicity was not captured in this trial",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "47"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "27"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1",
            "description": "Objective response according to RECIST v1.1. Best overall response of confirmed complete response (CR) or confirmed partial response (PR) recorded since first administration of trial medication and until the earliest of disease progression, death or start of next treatment in each part separately. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Percentage of participants with OR along with exact 95% Confidence Interval by Clopper and Pearson is presented.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel or of afatinib and vinorelbine. It was not planned to compare between the two types of combination therapies hence arm is combined",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Paclitaxel or Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "18",
                        "lowerLimit": "10",
                        "upperLimit": "28"
                      },
                      {
                        "groupId": "OG001",
                        "value": "31",
                        "lowerLimit": "17",
                        "upperLimit": "48"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Best Overall Response According to RECIST v1.1 (With Confirmation)",
            "description": "Best overall response was assessed according to RECIST version 1.1 and was calculated relative to the baseline of each respective part .Percentage of participants with best overall response along with exact 95% Confidence Interval by Clopper and Pearson is presented. Best overall response was defined as the best response recorded at any time from the first administration of drug to the End of Treatment (EOT). As Per RECIST v1.1 for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of the longest diameter of target lesions; progression, at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel or of afatinib and vinorelbine. It was not planned to compare between the two types of combination therapies hence arm is combined",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Paclitaxel or Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Complete response (CR)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1",
                        "lowerLimit": "0",
                        "upperLimit": "7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0",
                        "lowerLimit": "0",
                        "upperLimit": "9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Partial response (PR)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16",
                        "lowerLimit": "9",
                        "upperLimit": "27"
                      },
                      {
                        "groupId": "OG001",
                        "value": "31",
                        "lowerLimit": "17",
                        "upperLimit": "48"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Stable disease (SD)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "45",
                        "lowerLimit": "33",
                        "upperLimit": "57"
                      },
                      {
                        "groupId": "OG001",
                        "value": "46",
                        "lowerLimit": "30",
                        "upperLimit": "63"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Progressive disease",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28",
                        "lowerLimit": "19",
                        "upperLimit": "40"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10",
                        "lowerLimit": "3",
                        "upperLimit": "24"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Not evaluable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9",
                        "lowerLimit": "4",
                        "upperLimit": "19"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13",
                        "lowerLimit": "4",
                        "upperLimit": "27"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Best Overall Response According to RECIST v1.1 (Regardless of Confirmation)",
            "description": "Best overall response was assessed according to RECIST version 1.1 and was calculated relative to the baseline of each respective part (without clinical disease assessment) .Percentage of participants with best overall response along with exact 95% Confidence Interval by Clopper and Pearson is presented. Best overall response was defined as the best response recorded at any time from the first administration of drug to the End of Treatment (EOT). As Per RECIST v1.1 for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of the longest diameter of target lesions; progression, at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel or of afatinib and vinorelbine. It was not planned to compare between the two types of combination therapies hence arm is combined",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Paclitaxel or Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Complete response (CR)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1",
                        "lowerLimit": "0",
                        "upperLimit": "7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0",
                        "lowerLimit": "0",
                        "upperLimit": "9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Partial response (PR)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "19",
                        "lowerLimit": "11",
                        "upperLimit": "30"
                      },
                      {
                        "groupId": "OG001",
                        "value": "44",
                        "lowerLimit": "28",
                        "upperLimit": "60"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Stable disease (SD)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "42",
                        "lowerLimit": "31",
                        "upperLimit": "54"
                      },
                      {
                        "groupId": "OG001",
                        "value": "33",
                        "lowerLimit": "19",
                        "upperLimit": "50"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Progressive disease",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28",
                        "lowerLimit": "19",
                        "upperLimit": "40"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10",
                        "lowerLimit": "3",
                        "upperLimit": "24"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Not evaluable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9",
                        "lowerLimit": "4",
                        "upperLimit": "19"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13",
                        "lowerLimit": "4",
                        "upperLimit": "27"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Progression Free Survival (PFS)",
            "description": "Progression Free Survival is defined as the time from the drug start date to the date of 1st disease progression or death for monotherapy and 2nd disease progression or death from the drug start date of the combination therapy for combination therapy'. Median is calculated from the Kaplan-Meier curve.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel or of afatinib and vinorelbine. It was not planned to compare between the two types of combination therapies hence arm is combined",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Days",
            "timeFrame": "From drug start date in monotherapy to 1st disease progression and drug start date in combination therapy to 2nd disease progression",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Paclitaxel or Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "86.0",
                        "lowerLimit": "72.0",
                        "upperLimit": "127.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "135.0",
                        "lowerLimit": "95.0",
                        "upperLimit": "224.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Duration of Objective Response According to RECIST v1.1",
            "description": "Duration of objective response, defined as the time from first objective response to the time of progression or death. (regardless of confirmation). As Per RECIST v1.1 for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of the longest diameter of target lesions; progression, at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel or of afatinib and vinorelbine. It was not planned to compare between the two types of combination therapies hence arm is combined",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Days",
            "timeFrame": "From the first objective response to the time of progression or death, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Paclitaxel or Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "168.5",
                        "lowerLimit": "85.0",
                        "upperLimit": "253.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "125.0",
                        "lowerLimit": "73.0",
                        "upperLimit": "505.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Patients With Highest Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade of 3 or Higher",
            "description": "Percentage of patients with highest common terminology criteria for adverse events (CTCAE) version 3.0 Grade of 3 or higher.",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. The treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel, or of afatinib and vinorelbine.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              },
              {
                "id": "OG002",
                "title": "Afatinib and Paclitaxel Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "13"
                  },
                  {
                    "groupId": "OG002",
                    "value": "26"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "43"
                      },
                      {
                        "groupId": "OG001",
                        "value": "62"
                      },
                      {
                        "groupId": "OG002",
                        "value": "65"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline to End of Treatment in Systolic Blood Pressure (SBP)",
            "description": "Change from baseline to end of treatment in systolic blood pressure (SBP).",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. The treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel, or of afatinib and vinorelbine.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Millimeter of mercury (mmHg)",
            "timeFrame": "Baseline and End of treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              },
              {
                "id": "OG002",
                "title": "Afatinib and Paclitaxel Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "13"
                  },
                  {
                    "groupId": "OG002",
                    "value": "26"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.2",
                        "spread": "17.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "spread": "15.1"
                      },
                      {
                        "groupId": "OG002",
                        "value": "-3.7",
                        "spread": "12.1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline to End of Treatment in Diastolic Blood Pressure (DBP)",
            "description": "Change from baseline to end of treatment in diastolic blood pressure (DBP).",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. The treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel, or of afatinib and vinorelbine.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Millimeter of mercury (mmHg)",
            "timeFrame": "Baseline and End of treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              },
              {
                "id": "OG002",
                "title": "Afatinib and Paclitaxel Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "13"
                  },
                  {
                    "groupId": "OG002",
                    "value": "26"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.8",
                        "spread": "12.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.9",
                        "spread": "10.7"
                      },
                      {
                        "groupId": "OG002",
                        "value": "-1.6",
                        "spread": "10.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Patient With Possibly Clinically Significant (PCS) Laboratory Values",
            "description": "Number of patient with possibly clinically significant (PCS) laboratory values by functional group (haematology, differentials, coagulation, electrolytes, enzymes, and substrates). Acronyms Used: Prothrombin time-International normalized ratio (PT-INR), Alanine aminotransferase/Glutamic pyruvic transaminase (ALT/GPT) Serum glutamic pyruvic transaminase (SGPT), Aspartate aminotransferase/Glutamic-oxaloacetic transaminase (AST/GOT) Serum glutamic-oxaloacetic transaminase (SGOT)",
            "populationDescription": "The treated set for monotherapy comprised all patients who received at least 1 dose of afatinib. Number Analyzed are the patients with no possible clinically significant abnormality at baseline. Treated set for combination therapy comprised all patients who received at least 1 dose of each of afatinib and paclitaxel, or of afatinib and vinorelbine.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "From the initial dose of study drug until 28 days after end of the treatment period, up to 1562 days",
            "groups": [
              {
                "id": "OG000",
                "title": "Afatinib Monotherapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated."
              },
              {
                "id": "OG001",
                "title": "Afatinib and Vinorelbine Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              },
              {
                "id": "OG002",
                "title": "Afatinib and Paclitaxel Combination Therapy",
                "description": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "74"
                  },
                  {
                    "groupId": "OG001",
                    "value": "13"
                  },
                  {
                    "groupId": "OG002",
                    "value": "26"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Haematology - Haemoglobin (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5"
                      },
                      {
                        "groupId": "OG002",
                        "value": "17"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Haematology - White blood cell count (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9"
                      },
                      {
                        "groupId": "OG002",
                        "value": "13"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Haematology - Platelets (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Differentials, automatic - Neutrophils (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10"
                      },
                      {
                        "groupId": "OG002",
                        "value": "12"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Coagulation - PT-INR (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "63"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "25"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Electrolytes - Potassium (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "70"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Electrolytes - Potassium (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "70"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Electrolytes - Magnesium (low)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "63"
                      },
                      {
                        "groupId": "OG001",
                        "value": "12"
                      },
                      {
                        "groupId": "OG002",
                        "value": "25"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Enzymes - AST/GOT SGOT (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "70"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Enzymes - ALT/GPT SGPT (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3"
                      },
                      {
                        "groupId": "OG002",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Enzymes - Alkaline phosphatase (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1"
                      },
                      {
                        "groupId": "OG002",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Substrates - Creatinine (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Substrates - Bilirubin, total (high)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13"
                      },
                      {
                        "groupId": "OG002",
                        "value": "26"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00077376",
        "briefTitle": "Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",
        "officialTitle": "A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone(BMS-247550) and Carboplatin in Patients With HER2/Neu-Positive Metastatic Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2005-03"
        },
        "completionDateStruct": {
          "date": "2011-03"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "National Cancer Institute (NCI)"
        }
      },
      "conditionsModule": {
        "conditions": [
          "HER2-positive Breast Cancer",
          "Male Breast Cancer",
          "Recurrent Breast Cancer",
          "Stage IV Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 61,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "description": "All treated patients",
            "paramType": "MEDIAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "51",
                        "lowerLimit": "24",
                        "upperLimit": "81"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Age, Continuous",
            "description": "HER2+ patients only",
            "paramType": "MEDIAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "54",
                        "lowerLimit": "24",
                        "upperLimit": "81"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "description": "All treated patients",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "59"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study)",
            "description": "To assess objective response, it is necessary to estimate the overall tumor burden at baseline to which subsequent measurements will be compared. The same method of assessment and the same technique should be used to characterize each lesion at baseline and during follow-up.\n\nThe best overall response based on RECIST is the best response recorded from registration until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since registration. The best response was determined based on the tumor responses in target and nontarget lesions, with or without new lesions. To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. To be assigned a status of stable disease, measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks.",
            "populationDescription": "HER2+ patients",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Complete Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Partial Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No Change/ Stable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Progression",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "11"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Unevaluable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000"
                ],
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "paramType": "Objective response rate",
                "paramValue": "41",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "26",
                "ciUpperLimit": "58"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Objective Response for All Treated Patients (the Best Response a Patient Has Ever Experienced on Study)",
            "description": "To assess objective response, it is necessary to estimate the overall tumor burden at baseline to which subsequent measurements will be compared. The same method of assessment and the same technique should be used to characterize each lesion at baseline and during follow-up.\n\nThe best overall response based on RECIST is the best response recorded from registration until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since registration. The best response was determined based on the tumor responses in target and nontarget lesions, with or without new lesions. To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. To be assigned a status of stable disease, measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks.",
            "populationDescription": "All treated patients",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "timeFrame": "Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "59"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Compelete Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Partial Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "22"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "No Change/ Stable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "15"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Progression",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Unevaluable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000"
                ],
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "paramType": "Objective response rate",
                "paramValue": "44",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "31",
                "ciUpperLimit": "58"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Disease Progression for HER2+ Patients",
            "description": "This interval will be measured from the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression based on RECIST. Patients progression-free at last follow-up were censored.",
            "populationDescription": "HER2+ patients",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.1",
                        "lowerLimit": "5.5",
                        "upperLimit": "9.7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Disease Progression for All Treated Patients",
            "description": "This interval will be measured from the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression based on RECIST. Patients progression-free at last follow-up were censored.",
            "populationDescription": "All treated patients",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "59"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.2",
                        "lowerLimit": "6.3",
                        "upperLimit": "9.9"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Treatment Failure for HER2+ Patients",
            "description": "Time from study entry to the date at which a patient was removed from treatment due to progression, toxicity, refusal or death. If a patient was considered to be a major treatment violation or was taken off study as a non-protocol failure, the patient would be censored on the date he/she was removed from treatment.",
            "populationDescription": "HER2+ patients",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Assessed every cycle until treatment discontinuation",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.4",
                        "lowerLimit": "5.3",
                        "upperLimit": "6.2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Treatment Failure for All Treated Patients",
            "description": "Time from study entry to the date at which a patient was removed from treatment due to progression, toxicity, refusal or death. If a patient was considered to be a major treatment violation or was taken off study as a non-protocol failure, the patient would be censored on the date he/she was removed from treatment.",
            "populationDescription": "All treated patients",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Months",
            "timeFrame": "Assessed every cycle until treatment discontinuation",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "59"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.9",
                        "lowerLimit": "5.3",
                        "upperLimit": "7.6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Kaplan-Meier Estimate of Overall Survival at 3 Years for HER2+ Patients",
            "description": "Survival estimate from the Kaplan-Meier curve of the proportion of patients alive at 3 years.",
            "populationDescription": "HER2+ patients",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of Participants",
            "timeFrame": "Assessed every 3 months for 2 years, then every 6 months for 3 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "39"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "50",
                        "lowerLimit": "33.3",
                        "upperLimit": "66.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Kaplan-Meier Estimate of Overall Survival at 3 Years for All Treated Patients",
            "description": "Survival estimate from the Kaplan-Meier curve of the proportion of patients alive at 3 years.",
            "populationDescription": "All treated patients",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percentage of Participants",
            "timeFrame": "Assessed every 3 months for 2 years, then every 6 months for 3 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Trastuzumab/Ixabepilone/Carboplatin",
                "description": "During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV), H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker), and at least a 5-HT3 antagonist and dexamethasone.\n\nAfter completion of 24 weekly trastuzumab doses (induction therapy), trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose. Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "59"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "48",
                        "lowerLimit": "34.2",
                        "upperLimit": "61.6"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04980989",
        "briefTitle": "Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software",
        "officialTitle": "A Prospective Randomized Trial of Interactive Telemonitoring in the Follow-up of Patients Treated for Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2015-06-15"
        },
        "completionDateStruct": {
          "date": "2021-06-15"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Helsinki University Central Hospital"
        },
        "collaborators": [
          {
            "name": "University of Helsinki"
          },
          {
            "name": "Noona Healthcare"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer, Early-Onset"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 765,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {}
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01150513",
        "briefTitle": "Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer",
        "officialTitle": "Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2009-06"
        },
        "completionDateStruct": {
          "date": "2016-04"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Chinese Academy of Medical Sciences"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2",
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 320,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "China"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01467310",
        "briefTitle": "Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212",
        "officialTitle": "Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2012-01"
        },
        "completionDateStruct": {
          "date": "2016-03-21"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "UNC Lineberger Comprehensive Cancer Center"
        },
        "collaborators": [
          {
            "name": "GlaxoSmithKline"
          },
          {
            "name": "National Cancer Institute (NCI)"
          },
          {
            "name": "Susan G. Komen Breast Cancer Foundation"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "EARLY_PHASE1"
        ],
        "enrollmentInfo": {
          "count": 15,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01440855",
        "briefTitle": "Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting",
        "officialTitle": "Efficacy and Feasibility of a Psychosocial Intervention Within CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment (CCOP:Community Clinical Oncology Program)"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2005-02"
        },
        "completionDateStruct": {
          "date": "2009-10"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Fox Chase Cancer Center"
        },
        "collaborators": [
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Prostate Cancer",
          "Breast Cancer",
          "Colorectal Cancer",
          "Thoracic Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 340,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03313908",
        "briefTitle": "Radioguided Occult Lesion Localisation by Indocyanine Green",
        "officialTitle": "A Feasibility Study (ROLL-I) of Indocyanine Green (ICG) Fluorescence Mapping for Non-palpable Breast Cancers"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2017-10-17"
        },
        "completionDateStruct": {
          "date": "2018-12-19"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University Hospital, Montpellier"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer Female"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 10,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05364450",
        "briefTitle": "Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors",
        "officialTitle": "Acceptance and Commitment Therapy for Fear of Recurrence in Breast Cancer Survivors"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2021-08-17"
        },
        "completionDateStruct": {
          "date": "2024-07-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Indiana University"
        },
        "collaborators": [
          {
            "name": "Indiana University Health"
          },
          {
            "name": "Eskenazi Health"
          },
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasm",
          "Breast Cancer",
          "Breast Carcinoma",
          "Malignant Neoplasm of Breast",
          "Cancer of Breast",
          "Mammary Neoplasms, Human",
          "Human Mammary Carcinoma",
          "Malignant Tumor of Breast",
          "Mammary Cancer",
          "Mammary Carcinoma, Human",
          "Anxiety",
          "Fear"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 390,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06246084",
        "briefTitle": "INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy",
        "officialTitle": "INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2024-02-15"
        },
        "completionDateStruct": {
          "date": "2024-12-23"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Dana-Farber Cancer Institute"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Breast Cancer Female",
          "Breast Carcinoma"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 76,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02129049",
        "briefTitle": "Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children",
        "officialTitle": "Enhancing Connections Telephone Program: A Cancer Education Program for Parents"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2014-04"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Washington"
        },
        "collaborators": [
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Cervical Cancer",
          "Colon Cancer",
          "Leukemia",
          "Lymphoma",
          "Malignant Neoplasm",
          "Melanoma",
          "Rectal Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 35,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03832985",
        "briefTitle": "Pediatric Reporting of Adult-Onset Genomic Results",
        "officialTitle": "Reporting Adult-Onset Genomic Results to Pediatric Biobank Participants and Parents"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-11-25"
        },
        "completionDateStruct": {
          "date": "2024-10-31"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Geisinger Clinic"
        },
        "collaborators": [
          {
            "name": "National Human Genome Research Institute (NHGRI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Hereditary Breast and Ovarian Cancer Syndrome",
          "Lynch Syndrome",
          "Familial Hypercholesterolemia"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "EARLY_PHASE1"
        ],
        "enrollmentInfo": {
          "count": 427,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03852953",
        "briefTitle": "Under- and Overdiagnosis in BreastScreen Norway",
        "officialTitle": "Under- and Overdiagnosis in BreastScreen Norway"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2018-07-01"
        },
        "completionDateStruct": {
          "date": "2020-06-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Norwegian Institute of Public Health"
        },
        "collaborators": [
          {
            "name": "Extrastiftelsen"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 3915,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Norway"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04224272",
        "briefTitle": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer",
        "officialTitle": "Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-06-10"
        },
        "completionDateStruct": {
          "date": "2025-06-30"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Jazz Pharmaceuticals"
        }
      },
      "conditionsModule": {
        "conditions": [
          "HER2+/HR+ Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 51,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "54.7",
                        "spread": "10.9"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "49"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Asian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Black or African American",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "White",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "42"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Multiple",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Unknown",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Not Reported",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Number of Participants With Dose-Limiting Toxicities",
            "description": "Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant, or any combination of ZW25 and 1 or more of these drugs; and 2) meet the criteria as specified in the protocol.",
            "populationDescription": "Dose-limiting toxicities were assessed in participants with available data in the Safety Analysis Set.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Cycle 1 Day 1 to Day 28 (each cycle is 28 days)",
            "groups": [
              {
                "id": "OG000",
                "title": "ZW25 (Zanidatamab) + Palbociclib + Fulvestrant",
                "description": "Participants who received intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "8"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest",
            "description": "A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decreases in LVEF greater than or equal to 10 percentage points from baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis.",
            "populationDescription": "Safety data were assessed in the Safety Analysis Set.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 2 years 10 months",
            "groups": [
              {
                "id": "OG000",
                "title": "ZW25 (Zanidatamab) + Palbociclib + Fulvestrant",
                "description": "Participants who received an intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "51"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "TEAE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "51"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "SAE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "AESI",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events",
            "description": "A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0.",
            "populationDescription": "Treatment-emergent adverse events were assessed in the Safety Analysis Set.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Baseline from the start of dosing of any study drug up until 30 days after last study dose, up to approximately 2 years 10 months.",
            "groups": [
              {
                "id": "OG000",
                "title": "ZW25 (Zanidatamab) + Palbociclib + Fulvestrant",
                "description": "Participants who received an intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "51"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Any Blood and Lymphatic System Disorders AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "20"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Neutropenia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Anaemia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Thrombocytopenia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Gastrointestinal Disorder AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Diarrhoea",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Abdominal pain",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Duodenal ulcer",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Gastric ulcer",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Nausea",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Small intestinal obstruction",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Stomatitis",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Vomiting",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Investigation AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Neutrophil count decreased",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "11"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Ejection fraction decreased",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Transaminases increased",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "White blood cell count decreased",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Metabolism and Nutrition Disorder AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hypokalaemia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hypomagnesaemia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hypercalcaemia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any General Disorders and Administration Site Conditions AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Fatigue",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Pyrexia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Infections and Infestations AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "COVID-19 pneumonia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Psoas abscess",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Staphylococcal bacteraemia",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Respiratory, Thoracic and Mediastinal Disorder AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Pleural effusion",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Pneumothorax",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Renal and Urinary Disorder AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Acute kidney injury",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Any Skin and Subcutaneous Tissue Disorder AE",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Rash maculo-papular",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Progression-free Survival 6",
            "description": "The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).",
            "populationDescription": "Progression-free survival 6 will be assessed in the Safety Analysis Set.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "6 months from first dose of any study drug to the date of documented disease progression or death",
            "groups": [
              {
                "id": "OG000",
                "title": "ZW25 (Zanidatamab) + Palbociclib + Fulvestrant",
                "description": "Participants who received an intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "51"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "34"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Maximum Serum Concentration of ZW25",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Cycle 1, Days 1, 2, 5, 15; Cycle 2, Days 1 and 15; Day 1 of all subsequent cycles (each cycle is 28 days); and end of treatment, up to approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Trough Concentration of ZW25",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Cycle 1, Days 1, 2, 5, 15; Cycle 2, Days 1 and 15; Day 1 of all subsequent cycles (each cycle is 28 days); and end of treatment, up to approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Incidence of Anti-drug Antibodies (ADAs)",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Cycles 1 and 2, Day 15; Day 1 of all subsequent cycles (each cycle is 28 days); end of treatment, 30 days post-last dose (safety follow up), and every 8 weeks (efficacy follow up), up to approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Objective Response Rate",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Duration of Response",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Disease Control Rate",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Progression-free Survival",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Overall Survival",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Incidence of Lab Abnormalities",
            "reportingStatus": "NOT_POSTED",
            "anticipatedPostingDate": "2026-10",
            "timeFrame": "Baseline up to end of study, approximately 5 years 4 months",
            "denomUnitsSelected": "Participants"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05583981",
        "briefTitle": "Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery",
        "officialTitle": "Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2021-12-01"
        },
        "completionDateStruct": {
          "date": "2022-06-15"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Ohio State University Comprehensive Cancer Center"
        },
        "collaborators": [
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Carcinoma"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 31,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00543764",
        "briefTitle": "Intraoperative Pathway in DIEP Flap Breast Reconstruction",
        "officialTitle": "Intraoperative Pathway in DIEP Flap Breast Reconstruction"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2005-01"
        },
        "completionDateStruct": {
          "date": "2011-02"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Beth Israel Deaconess Medical Center"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 150,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Categorical",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "<=18 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "100"
                      },
                      {
                        "groupId": "BG001",
                        "value": "50"
                      },
                      {
                        "groupId": "BG002",
                        "value": "150"
                      }
                    ]
                  },
                  {
                    "title": ">=65 years",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex/Gender, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "paticipants",
            "classes": [
              {
                "title": "Female",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "100"
                      },
                      {
                        "groupId": "BG001",
                        "value": "50"
                      },
                      {
                        "groupId": "BG002",
                        "value": "150"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Male",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Operative Time",
            "description": "Length of Time in surgery",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "hours",
            "timeFrame": "3 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Pre Pathway",
                "description": "Patients prior to pathway implementation"
              },
              {
                "id": "OG001",
                "title": "Post Pathway",
                "description": "Patients after pathway implementation"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "100"
                  },
                  {
                    "groupId": "OG001",
                    "value": "50"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.2",
                        "lowerLimit": "7.8",
                        "upperLimit": "8.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.9",
                        "lowerLimit": "6.3",
                        "upperLimit": "7.5"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02597452",
        "briefTitle": "Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner",
        "officialTitle": "Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2014-03"
        },
        "completionDateStruct": {
          "date": "2017-12-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Pennsylvania"
        },
        "collaborators": [
          {
            "name": "UE LifeSciences Inc."
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 516,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "58",
                        "lowerLimit": "30",
                        "upperLimit": "89"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "486"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "17"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "468"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "9"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "153"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "312"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "486"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations (CBE)by Estimating the Sensitivity of the Device Using Imaging Results",
            "description": "comparing the calculated the sensitivities or the percentage of true positive breast lesions (based on imaging results) of the iBE and CBE",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of true positive lesions",
            "timeFrame": "approximately one month after imaging scan",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "486"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "34.3"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations by Estimating the Specificity of the Device Using Imaging Results",
            "description": "comparing the calculated the specificities or the percentage of true negative lesions (based on imaging results) of the iBE and CBE",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of true negative lesions",
            "timeFrame": "approximately one month after imaging",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "486"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "80.3"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Position of the Breast Lesion as Measured by iBE and Mammography",
            "description": "agreement of the position of the lesion, defined by time coordinate measured by iBE and mammography or ultrasound that fall within a 3 hour time quadrants on a clock of each other.",
            "populationDescription": "Number of subjects who had a lesion identified by iBE and mammogram, ultrasound, or MRI.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_UNITS",
            "unitOfMeasure": "lesions",
            "timeFrame": "approximately one month after imaging",
            "typeUnitsAnalyzed": "lesions",
            "denomUnitsSelected": "lesions",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "5"
                  }
                ]
              },
              {
                "units": "lesions",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "4"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Size Detection of the Breast Lesions Identified by iBE",
            "description": "The size detected of the breast lesion (cm) by mammogram or ultrasound",
            "populationDescription": "The size was not measured by iBE. Only 4 of the 7 lesions were detected by iBE and size data was not available to analyze.",
            "reportingStatus": "POSTED",
            "timeFrame": "approximately one month after imaging",
            "typeUnitsAnalyzed": "lesions",
            "denomUnitsSelected": "lesions",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "0"
                  }
                ]
              },
              {
                "units": "lesions",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "0"
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Inter-rate Reliability of the iBE and the CBE Number of Lesions Detected",
            "description": "comparing the number of breast lesions detected two independent healthcare professionals consecutive evaluations of the same patient with the iBE device and clinical breast exam",
            "populationDescription": "Difficulty enrolling patients for this outcome as a result of the participants undergoing the iBE and CBE twice by two different healthcare professionals. Subjects declined to continue after first healthcare professional exams was complete. Comparison data between healthcare professionals was not available to analyze.",
            "reportingStatus": "POSTED",
            "timeFrame": "through study completion an average of 18 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "0"
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Inter-rate Reliability of the iBE and the CBE Position of Lesions Detected",
            "description": "comparing the position(s) results of two independent healthcare professionals consecutive evaluations of the same patient with the iBE device and clinical breast exam",
            "populationDescription": "Difficulty enrolling patients for this outcome as a result of the participants undergoing the iBE and CBE twice by two different healthcare professionals. Subjects declined to continue after first healthcare professional exams was complete. Comparison data between healthcare professionals was not available to analyze.",
            "reportingStatus": "POSTED",
            "timeFrame": "through study completion an average of 18 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "0"
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Post-stratification of the Analysis of the Reliability by Breast Imaging Reporting and Data System Level",
            "description": "breakdown of the iBE clinically relevant findings and negative findings by the BIRAD levels determination from the gold standard final results",
            "populationDescription": "The specificity of iBE relevant findings (BIRADs 0, 3-5) vs benign findings (BIRADS 1, 2) from the results of mammography",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "through study completion an average of 18 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Intelligent Breast Exam, iBE",
                "description": "Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.\n\nintelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "486"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "title": "iBE true positive findings",
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12"
                      }
                    ]
                  },
                  {
                    "title": "iBE true negative findings",
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "362"
                      }
                    ]
                  },
                  {
                    "title": "iBE false positive findings",
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "89"
                      }
                    ]
                  },
                  {
                    "title": "iBE flase negative findings",
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "23"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01400438",
        "briefTitle": "Experience of the Patient Treated With Trastuzumab (Herceptin \u00ae) as Adjuvant for Breast Cancer",
        "officialTitle": "Experience of the Patient Treated With Trastuzumab (Herceptin \u00ae) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2011-07"
        },
        "completionDateStruct": {
          "date": "2015-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Centre Francois Baclesse"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 70,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00416715",
        "briefTitle": "Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",
        "officialTitle": "A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara\u00ae )"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2006-10"
        },
        "completionDateStruct": {
          "date": "2010-05"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Washington"
        },
        "collaborators": [
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Arthralgia",
          "Musculoskeletal Complications",
          "Pain",
          "Recurrent Breast Cancer",
          "Stage I Breast Cancer",
          "Stage II Breast Cancer",
          "Stage IIIA Breast Cancer",
          "Stage IIIB Breast Cancer",
          "Stage IIIC Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 100,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEDIAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "56",
                        "lowerLimit": "42",
                        "upperLimit": "81"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "100"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "98"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "87"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness",
            "description": "Count of early breast cancer patients prescribed adjuvant letrozole that are vitamin D deficient and who experience myalgias, arthralgias and/or joint stiffness, assessed at baseline and 1 month after vitamin D repletion.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Baseline and 1 month post vitamin D repletion",
            "groups": [
              {
                "id": "OG000",
                "title": "Baseline",
                "description": "All patients that are evaluable for joint aches and vitamin D levels."
              },
              {
                "id": "OG001",
                "title": "Post Vitamin D Repletion (1 Month)",
                "description": "Patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "85"
                  },
                  {
                    "groupId": "OG001",
                    "value": "12"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Letrozole Serum Levels Before and After Vitamin D Repletion",
            "description": "Letrezole serum level concentration in patients that were vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.",
            "populationDescription": "Only considering those patients who were baseline vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "micro-grams/mL",
            "timeFrame": "Baseline and 1 month post vitamin D repletion",
            "groups": [
              {
                "id": "OG000",
                "title": "Baseline",
                "description": "Those receiving Letrozole + vitamin D3"
              },
              {
                "id": "OG001",
                "title": "Post Vitamin D Repletion (1 Month)",
                "description": "Those receiving Letrezole + vitamin D3"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "12"
                  },
                  {
                    "groupId": "OG001",
                    "value": "12"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "85",
                        "lowerLimit": "63",
                        "upperLimit": "100"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70",
                        "lowerLimit": "69",
                        "upperLimit": "105"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00193076",
        "briefTitle": "Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer",
        "officialTitle": "A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2003-11"
        },
        "completionDateStruct": {
          "date": "2008-10"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "SCRI Development Innovations, LLC"
        },
        "collaborators": [
          {
            "name": "Eli Lilly and Company"
          },
          {
            "name": "Genentech, Inc."
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE2"
        ],
        "enrollmentInfo": {
          "count": 96,
          "type": "ESTIMATED"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00020332",
        "briefTitle": "Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
        "officialTitle": "A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2000-10"
        },
        "completionDateStruct": {
          "date": "2003-03"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "National Cancer Institute (NCI)"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1",
          "PHASE2"
        ]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00874458",
        "briefTitle": "MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ",
        "officialTitle": "Ductal Carcinoma in Situ: Protocol Evaluating the Assessment of Extension of Disease by MRI"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2007-04"
        },
        "completionDateStruct": {
          "date": "2013-12"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Centre Antoine Lacassagne"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 40,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01587248",
        "briefTitle": "Use of Harmonic in Breast Surgery",
        "officialTitle": "Harmonic Scalpel vs. Electrocautery Dissection in Modified Radical Mastectomy: A Randomized Controlled Trial"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2010-03"
        },
        "completionDateStruct": {
          "date": "2011-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Aga Khan University"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Modified Radical Mastectomy"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 152,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Pakistan"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05716958",
        "briefTitle": "Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",
        "officialTitle": "Multi-Reader, Multi-Case, Cross-Over, Retrospective, Superiority, Pivotal Study to Evaluate Effectiveness of Lunit INSIGHT DBT in the Assistance of Detection and Diagnosis of Breast Cancer During 3D Mammography Interpretation"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2022-03-22"
        },
        "completionDateStruct": {
          "date": "2023-02-28"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Lunit Inc."
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 262,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04108117",
        "briefTitle": "Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction",
        "officialTitle": "Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction : an International Multicenter Pooled Analysis"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-05-14"
        },
        "completionDateStruct": {
          "date": "2022-05-18"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Severance Hospital"
        },
        "collaborators": [
          {
            "name": "European Institute of Oncology"
          },
          {
            "name": "Changhua Christian Hospital"
          },
          {
            "name": "Samsung Medical Center"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Postoperative Complications",
          "Recurrence",
          "Breast Neoplasms",
          "Breast Cancer",
          "BRCA1 Mutation",
          "BRCA2 Mutation",
          "Surgery",
          "Surgery--Complications"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 659,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "South Korea"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01304251",
        "briefTitle": "Effects of Short-term Fasting on Tolerance to Chemotherapy",
        "officialTitle": "Effects of Short-term Fasting on Tolerance to Adjuvant Chemotherapy in Breast Cancer Patients"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2011-03"
        },
        "completionDateStruct": {
          "date": "2015-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Leiden University Medical Center"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 13,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Netherlands"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00416572",
        "briefTitle": "Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",
        "officialTitle": "Adjustment to Breast Cancer Among Younger Women"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "1997-01"
        },
        "completionDateStruct": {
          "date": "2006-04"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Carnegie Mellon University"
        },
        "collaborators": [
          {
            "name": "National Cancer Institute (NCI)"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 252,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {}
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "43.7",
                        "lowerLimit": "18",
                        "upperLimit": "50"
                      },
                      {
                        "groupId": "BG001",
                        "value": "44.2",
                        "lowerLimit": "18",
                        "upperLimit": "50"
                      },
                      {
                        "groupId": "BG002",
                        "value": "44.6",
                        "lowerLimit": "18",
                        "upperLimit": "50"
                      },
                      {
                        "groupId": "BG003",
                        "value": "44.2",
                        "lowerLimit": "18",
                        "upperLimit": "50"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "83"
                      },
                      {
                        "groupId": "BG001",
                        "value": "85"
                      },
                      {
                        "groupId": "BG002",
                        "value": "84"
                      },
                      {
                        "groupId": "BG003",
                        "value": "252"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Caucasian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "79"
                      },
                      {
                        "groupId": "BG001",
                        "value": "80"
                      },
                      {
                        "groupId": "BG002",
                        "value": "82"
                      },
                      {
                        "groupId": "BG003",
                        "value": "241"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "African-American",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "4"
                      },
                      {
                        "groupId": "BG001",
                        "value": "3"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      },
                      {
                        "groupId": "BG003",
                        "value": "9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention).",
            "description": "Scores for the shortened form of the Center for Epidemiologic Studies Depression scale(CES-D) ranged from 0 (no depressive symptoms) to 24 (high levels of depressives symptoms) in the present sample.",
            "populationDescription": "All women who agreed to random assignment and completed all three assessments were retained in the analysis regardless of their level of group attendance.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Post-intervention(4 months post-intervention) and Final Follow-up(13 months post-intervention).",
            "groups": [
              {
                "id": "OG000",
                "title": "Education Intervention",
                "description": "Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enhance coping in productive ways."
              },
              {
                "id": "OG001",
                "title": "Nutrition Education Intervention",
                "description": "Participants attended 2-hr nutrition education sessions, once a month for 4 months. Each session provided information/ encouragement on setting and attaining goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems and living a healthy lifestyle."
              },
              {
                "id": "OG002",
                "title": "Control Condition",
                "description": "Participants received care as usual"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "70"
                  },
                  {
                    "groupId": "OG001",
                    "value": "78"
                  },
                  {
                    "groupId": "OG002",
                    "value": "76"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.83",
                        "spread": "5.32"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.74",
                        "spread": "5.94"
                      },
                      {
                        "groupId": "OG002",
                        "value": "6.70",
                        "spread": "5.84"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Post-intervention",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.65",
                        "spread": "5.53"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.70",
                        "spread": "5.45"
                      },
                      {
                        "groupId": "OG002",
                        "value": "6.87",
                        "spread": "5.84"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Final follow-up",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.07",
                        "spread": "4.99"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.36",
                        "spread": "4.49"
                      },
                      {
                        "groupId": "OG002",
                        "value": "6.88",
                        "spread": "6.19"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "> 0.05",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">0.05",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "=0.08",
                "statisticalMethod": "Regression, Linear",
                "paramType": "standardized beta",
                "paramValue": "-0.12",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "<0.001",
                "statisticalMethod": "Regression, Linear",
                "paramType": "standardized beta",
                "paramValue": "-0.23",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Perceived Physical Health (Measured With SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)",
            "description": "The Perceived Physical Health Component scale of the Medical Outcomes Study Short Form 36 (SF-36) consists of a norm-based weighted average of the following subscales: Physical functioning, bodily pain, role limitations due to physical problems and general health. In the present study, scores ranged from a maximum of 68 (high levels of perceived health) to a minimum of 24 (low levels of perceived health).",
            "populationDescription": "All women who agreed to random assignment and completed all three assessments were retained in the analysis regardless of their level of group attendance.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Post-intervention(4 months post-intervention), and Final Follow-up(13 months post-intervention)",
            "groups": [
              {
                "id": "OG000",
                "title": "Education Intervention",
                "description": "Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enhance coping in productive ways."
              },
              {
                "id": "OG001",
                "title": "Nutrition Education Intervention",
                "description": "Participants attended 2-hr nutrition education sessions, once a month for 4 months. Each session provided information/ encouragement on setting and attaining goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems and living a healthy lifestyle."
              },
              {
                "id": "OG002",
                "title": "Control Condition",
                "description": "Participants received care as usual"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "70"
                  },
                  {
                    "groupId": "OG001",
                    "value": "78"
                  },
                  {
                    "groupId": "OG002",
                    "value": "76"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "49.21",
                        "spread": "8.19"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50.38",
                        "spread": "8.26"
                      },
                      {
                        "groupId": "OG002",
                        "value": "49.16",
                        "spread": "8.26"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Post-intervention",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "52.03",
                        "spread": "7.02"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53.59",
                        "spread": "6.18"
                      },
                      {
                        "groupId": "OG002",
                        "value": "50.73",
                        "spread": "9.07"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Final follow-up",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "55.11",
                        "spread": "7.12"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53.90",
                        "spread": "5.55"
                      },
                      {
                        "groupId": "OG002",
                        "value": "50.93",
                        "spread": "9.14"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">0.50",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "=0.04",
                "statisticalMethod": "Regression, Linear",
                "paramType": "Standardized beta",
                "paramValue": "0.14",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between the education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "<0.001",
                "statisticalMethod": "Regression, Linear",
                "paramType": "Standardized beta",
                "paramValue": "0.25",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": "=0.02",
                "statisticalMethod": "Regression, Linear",
                "paramType": "Standardized beta",
                "paramValue": "0.15",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Mental Health (Measured With the SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)",
            "description": "The Mental Health Component Scale of the Medical Outcomes Study Short Form 36 (SF-36) consists of a norm-based weighted average of the following subscales: vitality, social functioning, role limitations due to emotional problems and mental health. In the present study, scores ranged from a maximum of 68 (high levels of mental health) to a minimum of 15 (low levels of mental health).",
            "populationDescription": "All women who agreed to random assignment and completed all three assessments were retained in the analysis regardless of their level of group attendance.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Post-intervention(4 months post-intervention), Final Follow-up(13 months post-intervention)",
            "groups": [
              {
                "id": "OG000",
                "title": "Education Intervention",
                "description": "Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enhance coping in productive ways."
              },
              {
                "id": "OG001",
                "title": "Nutrition Education Intervention",
                "description": "Participants attended 2-hr nutrition education sessions, once a month for 4 months. Each session provided information/ encouragement on setting and attaining goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems and living a healthy lifestyle."
              },
              {
                "id": "OG002",
                "title": "Control Condition",
                "description": "Participants received care as usual"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "70"
                  },
                  {
                    "groupId": "OG001",
                    "value": "78"
                  },
                  {
                    "groupId": "OG002",
                    "value": "76"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "45.63",
                        "spread": "10.77"
                      },
                      {
                        "groupId": "OG001",
                        "value": "46.91",
                        "spread": "11.18"
                      },
                      {
                        "groupId": "OG002",
                        "value": "45.76",
                        "spread": "10.69"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Post-Intervention",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "50.47",
                        "spread": "9.13"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50.38",
                        "spread": "9.06"
                      },
                      {
                        "groupId": "OG002",
                        "value": "49.27",
                        "spread": "9.06"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Final Follow-up",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "48.64",
                        "spread": "10.72"
                      },
                      {
                        "groupId": "OG001",
                        "value": "51.26",
                        "spread": "8.27"
                      },
                      {
                        "groupId": "OG002",
                        "value": "49.48",
                        "spread": "8.27"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">.05",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">0.05",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG000",
                  "OG002"
                ],
                "groupDescription": "Comparison between education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">0.05",
                "statisticalMethod": "Regression, Linear"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG002"
                ],
                "groupDescription": "Comparison between nutrition education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.",
                "testedNonInferiority": false,
                "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                "pValue": ">0.05",
                "statisticalMethod": "Regression, Linear"
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03583944",
        "briefTitle": "A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",
        "officialTitle": "Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2018-03-28"
        },
        "completionDateStruct": {
          "date": "2019-06-28"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Eisai Inc."
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE4"
        ],
        "enrollmentInfo": {
          "count": 200,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          },
          {
            "country": "India"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03015649",
        "briefTitle": "Long Term Use of SAVI SCOUT: Pilot Study",
        "officialTitle": "Evaluation of Longer Duration Use of the SAVI SCOUT Surgical Guidance System for Excision of Breast and Axillary Lesions in Neo-adjuvant Therapy Patients: A Pilot Study"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2017-02-03"
        },
        "completionDateStruct": {
          "date": "2019-04-04"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Envision Healthcare Scientific Intelligence, Inc."
        },
        "collaborators": [
          {
            "name": "Cianna Medical, Inc."
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Diseases"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 34,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "FULL_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "50",
                        "lowerLimit": "28",
                        "upperLimit": "74"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "34"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Caucasian",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "10"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "African American",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Hispanic",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "11"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Node Positive",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "23"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Number of Participants Considered to Have a Successful Surgery",
            "description": "The primary endpoint of this study is successful surgery. Successful surgery (defined as one where the device stays in place and can be removed successfully during surgery) when this device is placed 31 - 365 days prior to surgery. Unsuccessful surgery is defined as one where the device does not stay in place and/or cannot be removed successfully during surgery) when this device is placed 31 - 365 days prior to surgery.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "31 - 365 days prior to surgery",
            "groups": [
              {
                "id": "OG000",
                "title": "SCOUT Device",
                "description": "All study participants received the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Each participant underwent the SAVI SCOUT Surgical Guidance System procedure."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "34"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "34"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00721058",
        "briefTitle": "Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.",
        "officialTitle": "Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer."
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2008-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Maastricht Radiation Oncology"
        },
        "collaborators": [
          {
            "name": "Atrium Medical Center"
          },
          {
            "name": "Maasland Hospital"
          },
          {
            "name": "Maastricht University Medical Center"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 60,
          "type": "ESTIMATED"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Netherlands"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02524548",
        "briefTitle": "SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors",
        "officialTitle": "Improving Medication Adherence With Adjuvant Aromatase Inhibitor in Women With Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2015-05"
        },
        "completionDateStruct": {
          "date": "2020-01"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "National University of Singapore"
        },
        "collaborators": [
          {
            "name": "Singapore Cancer Society"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Medication Adherence"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 244,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Singapore"
          },
          {
            "country": "Singapore"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05882578",
        "briefTitle": "Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals",
        "officialTitle": "Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2023-01-12"
        },
        "completionDateStruct": {
          "date": "2023-07-31"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Tigers Running Club"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer",
          "Cancer Survivors"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 74,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Spain"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02586025",
        "briefTitle": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel",
        "officialTitle": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2016-03-14"
        },
        "completionDateStruct": {
          "date": "2022-03-14"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Hoffmann-La Roche"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 329,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "China"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "48.4",
                        "spread": "9.7"
                      },
                      {
                        "groupId": "BG001",
                        "value": "49.5",
                        "spread": "9.1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "48.8",
                        "spread": "9.5"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Age, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "<40 years old",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "40"
                      },
                      {
                        "groupId": "BG001",
                        "value": "18"
                      },
                      {
                        "groupId": "BG002",
                        "value": "58"
                      }
                    ]
                  },
                  {
                    "title": "40-49 years old",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "75"
                      },
                      {
                        "groupId": "BG001",
                        "value": "40"
                      },
                      {
                        "groupId": "BG002",
                        "value": "115"
                      }
                    ]
                  },
                  {
                    "title": "50-64 years old",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "96"
                      },
                      {
                        "groupId": "BG001",
                        "value": "44"
                      },
                      {
                        "groupId": "BG002",
                        "value": "140"
                      }
                    ]
                  },
                  {
                    "title": "\u226565 years old",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "8"
                      },
                      {
                        "groupId": "BG001",
                        "value": "8"
                      },
                      {
                        "groupId": "BG002",
                        "value": "16"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Disease Category",
            "populationDescription": "ITT Population",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Early Stage",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "152"
                      },
                      {
                        "groupId": "BG001",
                        "value": "77"
                      },
                      {
                        "groupId": "BG002",
                        "value": "229"
                      }
                    ]
                  },
                  {
                    "title": "Locally Advanced",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "67"
                      },
                      {
                        "groupId": "BG001",
                        "value": "33"
                      },
                      {
                        "groupId": "BG002",
                        "value": "100"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Hormone Receptor Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "219"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "329"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Estrogen Receptor (ER) and Progesterone Receptor (PgR) Negative",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "105"
                      },
                      {
                        "groupId": "BG001",
                        "value": "54"
                      },
                      {
                        "groupId": "BG002",
                        "value": "159"
                      }
                    ]
                  },
                  {
                    "title": "Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Positive",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "114"
                      },
                      {
                        "groupId": "BG001",
                        "value": "56"
                      },
                      {
                        "groupId": "BG002",
                        "value": "170"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Baseline LVEF value",
            "description": "Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan.",
            "populationDescription": "Safety Evaluable Population; only participants who received at least one dose of study drug are included.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "percentage points of LVEF",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "BG000",
                        "value": "218"
                      },
                      {
                        "groupId": "BG001",
                        "value": "110"
                      },
                      {
                        "groupId": "BG002",
                        "value": "328"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "66.41",
                        "spread": "4.93"
                      },
                      {
                        "groupId": "BG001",
                        "value": "66.03",
                        "spread": "5.19"
                      },
                      {
                        "groupId": "BG002",
                        "value": "66.28",
                        "spread": "5.01"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)",
            "description": "This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \\[AJCC\\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel, 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "39.3",
                        "lowerLimit": "32.76",
                        "upperLimit": "46.08"
                      },
                      {
                        "groupId": "OG001",
                        "value": "21.8",
                        "lowerLimit": "14.51",
                        "upperLimit": "30.70"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0014",
                "pValueComment": "Two-sided significance level of 5%",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "statisticalComment": "Stratified by disease category (early-stage and locally advanced) and hormone-receptor status (positive for ER and/or PgR or negative for both)",
                "paramType": "Difference in response rates",
                "paramValue": "17.45",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "6.89",
                "ciUpperLimit": "28.01",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With tpCR as Assessed by the Local Pathologist",
            "description": "This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel, 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "39.3",
                        "lowerLimit": "32.76",
                        "upperLimit": "46.08"
                      },
                      {
                        "groupId": "OG001",
                        "value": "20.9",
                        "lowerLimit": "13.74",
                        "upperLimit": "29.70"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0008",
                "pValueComment": "Two-sided significance level of 5%",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "statisticalComment": "Stratified by disease category (early-stage and locally advanced) and hormone-receptor status (positive for ER and/or PgR or negative for both)",
                "paramType": "Difference in response rates",
                "paramValue": "18.36",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "7.89",
                "ciUpperLimit": "28.83",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC",
            "description": "This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "42.0",
                        "lowerLimit": "35.39",
                        "upperLimit": "48.85"
                      },
                      {
                        "groupId": "OG001",
                        "value": "23.6",
                        "lowerLimit": "16.06",
                        "upperLimit": "32.68"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0010",
                "pValueComment": "Two-sided significance level of 5%",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "statisticalComment": "Stratified by disease category (early-stage and locally advanced) and hormone-receptor status (positive for ER and/or PgR or negative for both)",
                "paramType": "Difference in response rates",
                "paramValue": "18.37",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "7.60",
                "ciUpperLimit": "29.15",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With bpCR as Assessed by the Local Pathologist",
            "description": "This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "41.6",
                        "lowerLimit": "34.95",
                        "upperLimit": "48.39"
                      },
                      {
                        "groupId": "OG001",
                        "value": "22.7",
                        "lowerLimit": "15.28",
                        "upperLimit": "31.70"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0006",
                "pValueComment": "Two-sided significance level of 5%",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "statisticalComment": "Stratified by disease category (early-stage and locally advanced) and hormone-receptor status (positive for ER and/or PgR or negative for both)",
                "paramType": "Difference in response rates",
                "paramValue": "18.83",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "8.14",
                "ciUpperLimit": "29.51",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",
            "description": "Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Complete Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "11.0",
                        "lowerLimit": "7.15",
                        "upperLimit": "15.87"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.0",
                        "lowerLimit": "5.10",
                        "upperLimit": "17.19"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Partial Response",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "77.6",
                        "lowerLimit": "71.52",
                        "upperLimit": "82.97"
                      },
                      {
                        "groupId": "OG001",
                        "value": "68.2",
                        "lowerLimit": "58.62",
                        "upperLimit": "76.74"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Stable Disease",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.2",
                        "lowerLimit": "4.94",
                        "upperLimit": "12.68"
                      },
                      {
                        "groupId": "OG001",
                        "value": "19.1",
                        "lowerLimit": "12.22",
                        "upperLimit": "27.69"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Progressive Disease",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.5",
                        "lowerLimit": "0.01",
                        "upperLimit": "2.52"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.8",
                        "lowerLimit": "0.22",
                        "upperLimit": "6.41"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Missing or Unevaluable",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.7",
                        "lowerLimit": "NA",
                        "upperLimit": "NA",
                        "comment": "95% confidence intervals were only calculated for clinical responses."
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.9",
                        "lowerLimit": "NA",
                        "upperLimit": "NA",
                        "comment": "95% confidence intervals were only calculated for clinical responses."
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1",
            "description": "An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "At surgery (Cycle 4 Days 22-35)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "88.6",
                        "lowerLimit": "83.61",
                        "upperLimit": "92.47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "78.2",
                        "lowerLimit": "69.30",
                        "upperLimit": "85.49"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0125",
                "pValueComment": "Two-sided significance level of 5%",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "statisticalComment": "Stratified by disease category (early-stage and locally advanced) and hormone-receptor status (positive for ER and/or PgR or negative for both)",
                "paramType": "Difference in response rates",
                "paramValue": "10.40",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "1.12",
                "ciUpperLimit": "19.69",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years",
            "description": "Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 \\& 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year \\& then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive \\& event-free.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for an EFS event at that timepoint. Different participants may have contributed data for each timepoint.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "estimate of percentage of participants",
            "timeFrame": "From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "1 Year",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "204"
                      },
                      {
                        "groupId": "OG001",
                        "value": "93"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "98.62",
                        "lowerLimit": "97.06",
                        "upperLimit": "100.00"
                      },
                      {
                        "groupId": "OG001",
                        "value": "90.46",
                        "lowerLimit": "84.82",
                        "upperLimit": "96.09"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "3 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "176"
                      },
                      {
                        "groupId": "OG001",
                        "value": "80"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "88.85",
                        "lowerLimit": "84.55",
                        "upperLimit": "93.15"
                      },
                      {
                        "groupId": "OG001",
                        "value": "79.68",
                        "lowerLimit": "71.91",
                        "upperLimit": "87.45"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "5 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "151"
                      },
                      {
                        "groupId": "OG001",
                        "value": "67"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "84.80",
                        "lowerLimit": "79.86",
                        "upperLimit": "89.73"
                      },
                      {
                        "groupId": "OG001",
                        "value": "73.70",
                        "lowerLimit": "65.17",
                        "upperLimit": "82.23"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Hazard Ratio for EFS Event in the Pertuzumab arm vs. Placebo arm",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0140",
                "statisticalMethod": "Stratified log-rank",
                "statisticalComment": "Two-sided log-rank test used, stratified by disease category (early-stage/locally advanced) \\& hormone-receptor status (ER+ \\&/or PgR+ or ER- \\& PgR-)",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.53",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.32",
                "ciUpperLimit": "0.89",
                "estimateComment": "The hazard ratio was calculated by stratified Cox proportional hazards model."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in EFS Event-Free Rates at 1 year",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0062",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in EFS Event-Free Rates",
                "paramValue": "-8.16",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-14.00",
                "ciUpperLimit": "-2.32",
                "estimateComment": "The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in EFS Event-Free Rates at 3 years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0429",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in EFS Event-Free Rates",
                "paramValue": "-9.17",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-18.05",
                "ciUpperLimit": "-0.29",
                "estimateComment": "The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in EFS Event-Free Rates at 5 Years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0274",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in EFS Event-Free Rates",
                "paramValue": "-11.10",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-20.95",
                "ciUpperLimit": "-1.24",
                "estimateComment": "The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years",
            "description": "Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment. Overall number of participants analyzed are unique number of participants who underwent surgery. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for a DFS event at that timepoint. Different participants may have contributed data for each timepoint.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "estimate of percentage of participants",
            "timeFrame": "From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "210"
                  },
                  {
                    "groupId": "OG001",
                    "value": "105"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "1 Year",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "197"
                      },
                      {
                        "groupId": "OG001",
                        "value": "93"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "97.55",
                        "lowerLimit": "95.42",
                        "upperLimit": "99.67"
                      },
                      {
                        "groupId": "OG001",
                        "value": "92.08",
                        "lowerLimit": "86.81",
                        "upperLimit": "97.35"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "3 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "176"
                      },
                      {
                        "groupId": "OG001",
                        "value": "80"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "90.09",
                        "lowerLimit": "85.97",
                        "upperLimit": "94.22"
                      },
                      {
                        "groupId": "OG001",
                        "value": "81.10",
                        "lowerLimit": "73.44",
                        "upperLimit": "88.75"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "5 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "81"
                      },
                      {
                        "groupId": "OG001",
                        "value": "41"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "85.99",
                        "lowerLimit": "81.17",
                        "upperLimit": "90.80"
                      },
                      {
                        "groupId": "OG001",
                        "value": "75.02",
                        "lowerLimit": "66.53",
                        "upperLimit": "83.51"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Hazard Ratio for DFS Event in the Pertuzumab arm vs. Placebo arm",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0140",
                "statisticalMethod": "Stratified log-rank",
                "statisticalComment": "Two-sided log-rank test used, stratified by disease category (early-stage/locally advanced) \\& hormone-receptor status (ER+ \\&/or PgR+ or ER- \\& PgR-)",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.52",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.30",
                "ciUpperLimit": "0.88",
                "estimateComment": "The hazard ratio was calculated by stratified Cox proportional hazards model."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in DFS Event-Free Rates at 1 year",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0592",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in DFS Event-Free Rates",
                "paramValue": "-5.47",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-11.15",
                "ciUpperLimit": "0.21",
                "estimateComment": "The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in DFS Event-Free Rates at 3 years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0426",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in DFS Event-Free Rates",
                "paramValue": "-9.00",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-17.69",
                "ciUpperLimit": "-0.30",
                "estimateComment": "The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in DFS Event-Free Rates at 5 years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0276",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in DFS Event-Free Rates",
                "paramValue": "-10.97",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-20.73",
                "ciUpperLimit": "-1.21",
                "estimateComment": "The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years",
            "description": "Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.",
            "populationDescription": "ITT population included all participants who were enrolled regardless of whether they received any study treatment. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for an OS event at that timepoint. Different participants may have contributed data for each timepoint.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "estimate of percentage of participants",
            "timeFrame": "From Baseline to OS event or date last known to be alive at 1, 3, and 5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "219"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "1 Year",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "205"
                      },
                      {
                        "groupId": "OG001",
                        "value": "101"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "99.54",
                        "lowerLimit": "98.64",
                        "upperLimit": "100.00"
                      },
                      {
                        "groupId": "OG001",
                        "value": "100.00",
                        "lowerLimit": "100.00",
                        "upperLimit": "100.00"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "3 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "188"
                      },
                      {
                        "groupId": "OG001",
                        "value": "89"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "97.01",
                        "lowerLimit": "94.64",
                        "upperLimit": "99.37"
                      },
                      {
                        "groupId": "OG001",
                        "value": "90.99",
                        "lowerLimit": "85.37",
                        "upperLimit": "96.60"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "5 Years",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "160"
                      },
                      {
                        "groupId": "OG001",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "93.86",
                        "lowerLimit": "90.49",
                        "upperLimit": "97.23"
                      },
                      {
                        "groupId": "OG001",
                        "value": "89.97",
                        "lowerLimit": "84.06",
                        "upperLimit": "95.87"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Hazard Ratio for OS Event in the Pertuzumab arm vs. Placebo arm",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.1181",
                "statisticalMethod": "Stratified log-rank",
                "statisticalComment": "Two-sided log-rank test used, stratified by disease category (early-stage/locally advanced) \\& hormone-receptor status (ER+ \\&/or PgR+ or ER- \\& PgR-)",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.53",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.23",
                "ciUpperLimit": "1.19",
                "estimateComment": "The hazard ratio was calculated by stratified Cox proportional hazards model."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in OS Event-Free Rates at 1 year",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.3162",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in OS Event-Free Rates",
                "paramValue": "0.46",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.44",
                "ciUpperLimit": "1.36",
                "estimateComment": "The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in OS Event-Free Rates at 3 years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0529",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in OS Event-Free Rates",
                "paramValue": "-6.02",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-12.11",
                "ciUpperLimit": "0.08",
                "estimateComment": "The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              },
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "groupDescription": "Difference in OS Event-Free Rates at 5 years",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.2616",
                "statisticalMethod": "Z-test",
                "paramType": "Difference in OS Event-Free Rates",
                "paramValue": "-3.89",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-10.69",
                "ciUpperLimit": "2.90",
                "estimateComment": "The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period",
            "description": "The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of neoadjuvant study treatment and participants were grouped by the treatment they actually received.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "Baseline up to end of Cycle 4 (1 cycle = 21 days)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "218"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "97.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "96.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With at Least One AE During the Adjuvant Treatment Period",
            "description": "Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of adjuvant study treatment and participants were grouped by the treatment they actually received. Overall number analyzed is the number of participants with data available for analysis.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "208"
                  },
                  {
                    "groupId": "OG001",
                    "value": "103"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "98.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "98.1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period",
            "description": "The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "218"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.3"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants Who Experienced a Primary Cardiac Event",
            "description": "A primary cardiac event is defined as heart failure (New York Heart Association \\[NYHA\\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "From Baseline until end of study (up to 6 years)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "218"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants Who Experienced a Secondary Cardiac Event",
            "description": "A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "From Baseline until end of study (up to 6 years)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "218"
                  },
                  {
                    "groupId": "OG001",
                    "value": "110"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Maximum Change From Baseline in LVEF",
            "description": "LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received. Overall number analyzed is the number of participants with data available for analysis.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "percentage points of LVEF",
            "timeFrame": "Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "215"
                  },
                  {
                    "groupId": "OG001",
                    "value": "109"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.55",
                        "spread": "5.22"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.20",
                        "spread": "6.08"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "OTHER",
                "paramType": "Mean Difference (Final Values)",
                "paramValue": "-0.35",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.62",
                "ciUpperLimit": "0.93",
                "estimateComment": "Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in LVEF Over Time",
            "description": "LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.",
            "populationDescription": "Safety evaluable population included all participants who received at least one dose of study drugs. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "percentage points of LVEF",
            "timeFrame": "Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)",
            "groups": [
              {
                "id": "OG000",
                "title": "Pertuzumab, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel 75 mg/m\\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days)."
              },
              {
                "id": "OG001",
                "title": "Placebo, Trastuzumab, and Chemotherapy",
                "description": "Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\\^2, epirubicin 90-120 mg/m\\^2, and cyclophosphamide 500-600 mg/m\\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days)."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "213"
                  },
                  {
                    "groupId": "OG001",
                    "value": "108"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Cycle 2 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "213"
                      },
                      {
                        "groupId": "OG001",
                        "value": "108"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.62",
                        "lowerLimit": "-1.35",
                        "upperLimit": "0.11"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.29",
                        "lowerLimit": "-0.89",
                        "upperLimit": "1.46"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cycle 4 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "212"
                      },
                      {
                        "groupId": "OG001",
                        "value": "108"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.02",
                        "lowerLimit": "-1.72",
                        "upperLimit": "-0.32"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.09",
                        "lowerLimit": "-1.03",
                        "upperLimit": "1.22"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cycle 5 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "200"
                      },
                      {
                        "groupId": "OG001",
                        "value": "102"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.96",
                        "lowerLimit": "-1.70",
                        "upperLimit": "-0.22"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.07",
                        "lowerLimit": "-1.12",
                        "upperLimit": "1.26"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cycle 8 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "196"
                      },
                      {
                        "groupId": "OG001",
                        "value": "97"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.63",
                        "lowerLimit": "-2.44",
                        "upperLimit": "-0.81"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.18",
                        "lowerLimit": "-2.30",
                        "upperLimit": "-0.05"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cycle 11 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "203"
                      },
                      {
                        "groupId": "OG001",
                        "value": "94"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.38",
                        "lowerLimit": "-2.16",
                        "upperLimit": "-0.61"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.65",
                        "lowerLimit": "-1.91",
                        "upperLimit": "0.62"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cycle 20 Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "183"
                      },
                      {
                        "groupId": "OG001",
                        "value": "89"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.22",
                        "lowerLimit": "-2.05",
                        "upperLimit": "-0.38"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.18",
                        "lowerLimit": "-2.56",
                        "upperLimit": "0.20"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01216111",
        "briefTitle": "Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)",
        "officialTitle": "A Prospective\uff0c Randomized\uff0c Open-label\uff0c Multicentric\uff0cphaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2011-01-01"
        },
        "completionDateStruct": {
          "date": "2016-04-20"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Fudan University"
        },
        "collaborators": [
          {
            "name": "Chinese Anti-Cancer Association"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Triple Negative Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 647,
          "type": "ACTUAL"
        }
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT07052734",
        "briefTitle": "Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients",
        "officialTitle": "A Multicenter Retrospective Analysis of the Miti-gene Recurrence Score in Early-Stage Invasive HR-Positive, HER2-Negative Breast Cancer in China"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2024-12-01"
        },
        "completionDateStruct": {
          "date": "2025-06-18"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Sun Yat-sen University"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "enrollmentInfo": {
          "count": 2843,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "China"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00514306",
        "briefTitle": "Study of Intermittent OSI-906 Dosing",
        "officialTitle": "A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2007-07-05"
        },
        "completionDateStruct": {
          "date": "2010-09-20"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Astellas Pharma Inc"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Advanced Solid Tumors"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 79,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United Kingdom"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03333785",
        "briefTitle": "Randomized Trial of eOncoNote",
        "officialTitle": "Improving Cancer Care Together Through eOncoNote"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2018-02-05"
        },
        "completionDateStruct": {
          "date": "2021-02-17"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Toronto"
        },
        "collaborators": [
          {
            "name": "Ontario Clinical Oncology Group (OCOG)"
          },
          {
            "name": "Ottawa Regional Cancer Centre"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Communication Research",
          "Breast Cancer",
          "Prostate Cancer",
          "Colorectal Cancer",
          "Lung Cancer",
          "Program, Communication",
          "Remote Consultation"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 181,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Canada"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT01966471",
        "briefTitle": "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer",
        "officialTitle": "A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2014-01-31"
        },
        "completionDateStruct": {
          "date": "2021-06-04"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Hoffmann-La Roche"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "enrollmentInfo": {
          "count": 1846,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Australia"
          },
          {
            "country": "Belgium"
          },
          {
            "country": "Belgium"
          },
          {
            "country": "Bosnia and Herzegovina"
          },
          {
            "country": "Bosnia and Herzegovina"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Brazil"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Canada"
          },
          {
            "country": "Chile"
          },
          {
            "country": "Chile"
          },
          {
            "country": "Colombia"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "Czechia"
          },
          {
            "country": "El Salvador"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "France"
          },
          {
            "country": "Georgia"
          },
          {
            "country": "Georgia"
          },
          {
            "country": "Georgia"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Germany"
          },
          {
            "country": "Guatemala"
          },
          {
            "country": "Guatemala"
          },
          {
            "country": "Hong Kong"
          },
          {
            "country": "Hong Kong"
          },
          {
            "country": "Hong Kong"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Hungary"
          },
          {
            "country": "Israel"
          },
          {
            "country": "Israel"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Italy"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Japan"
          },
          {
            "country": "Mexico"
          },
          {
            "country": "Mexico"
          },
          {
            "country": "Mexico"
          },
          {
            "country": "Mexico"
          },
          {
            "country": "Norway"
          },
          {
            "country": "Norway"
          },
          {
            "country": "Panama"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Peru"
          },
          {
            "country": "Philippines"
          },
          {
            "country": "Philippines"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Poland"
          },
          {
            "country": "Romania"
          },
          {
            "country": "Romania"
          },
          {
            "country": "Romania"
          },
          {
            "country": "Romania"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Russia"
          },
          {
            "country": "Singapore"
          },
          {
            "country": "Singapore"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "South Korea"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Sweden"
          },
          {
            "country": "Switzerland"
          },
          {
            "country": "Switzerland"
          },
          {
            "country": "Switzerland"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Taiwan"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Thailand"
          },
          {
            "country": "Ukraine"
          },
          {
            "country": "Ukraine"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          },
          {
            "country": "United Kingdom"
          }
        ]
      }
    },
    "resultsSection": {
      "baselineCharacteristicsModule": {
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "51.6",
                        "spread": "10.8"
                      },
                      {
                        "groupId": "BG001",
                        "value": "51.9",
                        "spread": "10.8"
                      },
                      {
                        "groupId": "BG002",
                        "value": "51.7",
                        "spread": "10.8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "913"
                      },
                      {
                        "groupId": "BG001",
                        "value": "926"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1839"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "70"
                      },
                      {
                        "groupId": "BG001",
                        "value": "68"
                      },
                      {
                        "groupId": "BG002",
                        "value": "138"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "798"
                      },
                      {
                        "groupId": "BG001",
                        "value": "790"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1588"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "50"
                      },
                      {
                        "groupId": "BG001",
                        "value": "70"
                      },
                      {
                        "groupId": "BG002",
                        "value": "120"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      },
                      {
                        "groupId": "BG001",
                        "value": "12"
                      },
                      {
                        "groupId": "BG002",
                        "value": "24"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "267"
                      },
                      {
                        "groupId": "BG001",
                        "value": "275"
                      },
                      {
                        "groupId": "BG002",
                        "value": "542"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "15"
                      },
                      {
                        "groupId": "BG001",
                        "value": "8"
                      },
                      {
                        "groupId": "BG002",
                        "value": "23"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "558"
                      },
                      {
                        "groupId": "BG001",
                        "value": "565"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1123"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "63"
                      },
                      {
                        "groupId": "BG001",
                        "value": "65"
                      },
                      {
                        "groupId": "BG002",
                        "value": "128"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation",
            "description": "IDFS event was defined as the time from randomization until the date of first occurrence of one of the following: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer \\[bc\\] involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive bc recurrence (an invasive bc in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Contralateral or ipsilateral second primary invasive bc; Distant recurrence (evidence of bc in any anatomic site \\[other than the three sites mentioned above\\]) that has either been histologically confirmed or clinically/radiographically diagnosed as recurrent invasive bc; Death attributable to any cause, including bc, non-bc, or unknown cause. 3-year IDFS event-free rate per randomized treatment arms in the ITT population was estimated using the Kaplan-Meier method and estimated the probability of a participant being event-free after 3 years after randomization.",
            "populationDescription": "The ITT lymph node positive population was a subpopulation of the randomized participant population including patients with positive lymph node.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "Last participant randomized to data cut-off date of 27 November 2019 (approximately 70 months). The 3 year IDFS event-free rate was assessed based on the data collected for each participant considering the cut-off date mentioned above.",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "826"
                  },
                  {
                    "groupId": "OG001",
                    "value": "832"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "94.10",
                        "lowerLimit": "92.46",
                        "upperLimit": "95.73"
                      },
                      {
                        "groupId": "OG001",
                        "value": "92.75",
                        "lowerLimit": "90.95",
                        "upperLimit": "94.54"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.8270",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.97",
                "ciPctValue": "95",
                "ciLowerLimit": "0.71",
                "ciUpperLimit": "1.32"
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Invasive Disease-Free Survival (IDFS) in the Overall Population",
            "description": "IDFS event was defined as the time from randomization until the date of first occurrence of one of the following: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer \\[bc\\] involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive bc recurrence (an invasive bc in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Contralateral or ipsilateral second primary invasive bc; Distant recurrence (evidence of bc in any anatomic site \\[other than the three sites mentioned above\\]) that has either been histologically confirmed or clinically/radiographically diagnosed as recurrent invasive bc; Death attributable to any cause, including bc, non-bc, or unknown cause. 3-year IDFS event-free rate per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after randomization.",
            "populationDescription": "The ITT Population comprised all randomized patients, whether or not they received any study treatment or completed a full course of study treatment. Patients were analyzed according to their randomized treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "First participant randomized up to approximately 7.5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "918"
                  },
                  {
                    "groupId": "OG001",
                    "value": "928"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "94.22",
                        "lowerLimit": "92.68",
                        "upperLimit": "95.76"
                      },
                      {
                        "groupId": "OG001",
                        "value": "93.06",
                        "lowerLimit": "91.40",
                        "upperLimit": "94.73"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.9291",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "1.01",
                "ciPctValue": "95",
                "ciLowerLimit": "0.77",
                "ciUpperLimit": "1.34"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "IDFS Plus Second Primary Non-Breast Cancer",
            "description": "IDFS including second primary non-breast cancer was defined the same way as IDFS for the primary endpoint but including second primary non breast invasive cancer as an event (with the exception of non-melanoma skin cancers and carcinoma in situ (CIS) of any site).",
            "populationDescription": "The ITT Population comprised all randomized patients, whether or not they received any study treatment or completed a full course of study treatment. Patients were analyzed according to their randomized treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "Baseline up to approximately 70 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "918"
                  },
                  {
                    "groupId": "OG001",
                    "value": "928"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "93.43",
                        "lowerLimit": "91.79",
                        "upperLimit": "95.06"
                      },
                      {
                        "groupId": "OG001",
                        "value": "92.26",
                        "lowerLimit": "90.51",
                        "upperLimit": "94.02"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.8756",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.98",
                "ciPctValue": "95",
                "ciLowerLimit": "0.74",
                "ciUpperLimit": "1.30"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Disease-Free Survival (DFS)",
            "description": "DFS was defined as time between randomization and first occurrence of IDFS, second primary non-breast cancer and contralateral or ipsilateral ductal carcinoma in situ (DCIS).",
            "populationDescription": "The ITT Population comprised all randomized patients, whether or not they received any study treatment or completed a full course of study treatment. Patients were analyzed according to their randomized treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "Baseline up to approximately 70 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "918"
                  },
                  {
                    "groupId": "OG001",
                    "value": "928"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "93.32",
                        "lowerLimit": "91.67",
                        "upperLimit": "94.97"
                      },
                      {
                        "groupId": "OG001",
                        "value": "92.04",
                        "lowerLimit": "90.26",
                        "upperLimit": "93.81"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.9341",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.99",
                "ciPctValue": "95",
                "ciLowerLimit": "0.75",
                "ciUpperLimit": "1.31"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Distant Recurrence-Free Interval (DRFI)",
            "description": "DRFI was defined as time between randomization and first occurrence of distant breast cancer recurrence.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "Baseline up to approximately 70 months",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "918"
                  },
                  {
                    "groupId": "OG001",
                    "value": "928"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "95.23",
                        "lowerLimit": "93.82",
                        "upperLimit": "96.64"
                      },
                      {
                        "groupId": "OG001",
                        "value": "94.91",
                        "lowerLimit": "93.46",
                        "upperLimit": "96.36"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.4577",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "0.88",
                "ciPctValue": "95",
                "ciLowerLimit": "0.61",
                "ciUpperLimit": "1.25"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Overall Survival (OS)",
            "description": "OS was defined as the time from randomization to death due to any cause.",
            "populationDescription": "The ITT Population comprised all randomized patients, whether or not they received any study treatment or completed a full course of study treatment. Patients were analyzed according to their randomized treatment.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "Percent Probability",
            "timeFrame": "First participant randomized up to approximately 7.5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "918"
                  },
                  {
                    "groupId": "OG001",
                    "value": "928"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "96.03",
                        "lowerLimit": "94.72",
                        "upperLimit": "97.34"
                      },
                      {
                        "groupId": "OG001",
                        "value": "94.86",
                        "lowerLimit": "93.40",
                        "upperLimit": "96.32"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.2864",
                "statisticalMethod": "Log Rank",
                "paramType": "Hazard Ratio (HR)",
                "paramValue": "1.24",
                "ciPctValue": "95",
                "ciLowerLimit": "0.83",
                "ciUpperLimit": "1.84"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With Adverse Events",
            "description": "An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0).",
            "populationDescription": "The safety population included all randomized participants who received at least one full or partial dose of any study treatment. 8 participants were randomized but did not receive any study treatment (5 in the Anthracycline, Trastuzumab, Pertuzumab, and Taxane \\[AC-THP\\] arm, 3 in the Anthracycline, Trastuzumab Emtansine and Pertuzumab \\[AC-KP\\] arm). 16 participants in the AC-THP and 13 participants in the AC-KP arm only received AC but no HER2 targeted therapy and were assigned to the AC-THP arm.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Percentage of participants",
            "timeFrame": "From randomization to approximately 7.5 years",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "926"
                  },
                  {
                    "groupId": "OG001",
                    "value": "912"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "98.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "99.1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time",
            "description": "LVEF was assessed using either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans.",
            "populationDescription": "The safety population included all randomized participants who received at least one full or partial dose of any study treatment.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "First participant randomized up to approximately 7.5 years.",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "926"
                  },
                  {
                    "groupId": "OG001",
                    "value": "912"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Decrease from baseline <10 Ejection Fraction (EF) points",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "914"
                      },
                      {
                        "groupId": "OG001",
                        "value": "912"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "506"
                      },
                      {
                        "groupId": "OG001",
                        "value": "522"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Absolute value >= 50% and decrease from baseline >= 10 EF points",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "914"
                      },
                      {
                        "groupId": "OG001",
                        "value": "912"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "254"
                      },
                      {
                        "groupId": "OG001",
                        "value": "245"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Absolute value < 50% and decrease from baseline >= 10 EF points",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "914"
                      },
                      {
                        "groupId": "OG001",
                        "value": "912"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "35"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Absolute value < 50% and decrease from baseline >= 15 EF points",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "914"
                      },
                      {
                        "groupId": "OG001",
                        "value": "912"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "61"
                      },
                      {
                        "groupId": "OG001",
                        "value": "28"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score",
            "description": "The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \\[1 'very poor' to 7 'Excellent'\\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 7 - 15 points considered to be a clinically meaningful detioration to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).",
            "populationDescription": "The Patient Reported Outcome (PRO) Population includes participants with both a baseline assessment and at least one post-baseline assessment in any PRO items. The variation of the number of participants in the table reflects the number of participants with corresponding scores at the given visits and at baseline.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Units on a Scale",
            "timeFrame": "Baseline, Cycles 1, 2, 3, 4, 5, 9, 14, End of Treatment, Follow-up Month 6, Follow-up Month 12, Follow-up Month 18",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "869"
                  },
                  {
                    "groupId": "OG001",
                    "value": "891"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "888"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.2",
                        "spread": "17.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.6",
                        "spread": "16.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "835"
                      },
                      {
                        "groupId": "OG001",
                        "value": "857"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.2",
                        "spread": "27.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.8",
                        "spread": "26.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "15.2",
                        "spread": "27.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13.1",
                        "spread": "26.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "833"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "14.3",
                        "spread": "28.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.3",
                        "spread": "25.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "815"
                      },
                      {
                        "groupId": "OG001",
                        "value": "834"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16.2",
                        "spread": "29.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.4",
                        "spread": "25.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "826"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.0",
                        "spread": "28.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.0",
                        "spread": "26.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "792"
                      },
                      {
                        "groupId": "OG001",
                        "value": "792"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.7",
                        "spread": "23.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.2",
                        "spread": "25.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "772"
                      },
                      {
                        "groupId": "OG001",
                        "value": "750"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.2",
                        "spread": "23.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.4",
                        "spread": "25.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "806"
                      },
                      {
                        "groupId": "OG001",
                        "value": "810"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.5",
                        "spread": "22.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.6",
                        "spread": "25.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "744"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.3",
                        "spread": "20.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.4",
                        "spread": "20.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "738"
                      },
                      {
                        "groupId": "OG001",
                        "value": "722"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.2",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.3",
                        "spread": "20.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Appetite Loss",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "884"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9.6",
                        "spread": "19.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.0",
                        "spread": "19.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "835"
                      },
                      {
                        "groupId": "OG001",
                        "value": "855"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.4",
                        "spread": "22.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.0",
                        "spread": "26.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "812"
                      },
                      {
                        "groupId": "OG001",
                        "value": "821"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.1",
                        "spread": "25.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.9",
                        "spread": "23.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "812"
                      },
                      {
                        "groupId": "OG001",
                        "value": "829"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.0",
                        "spread": "24.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.2",
                        "spread": "22.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "811"
                      },
                      {
                        "groupId": "OG001",
                        "value": "829"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.5",
                        "spread": "24.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.6",
                        "spread": "23.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "813"
                      },
                      {
                        "groupId": "OG001",
                        "value": "820"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.5",
                        "spread": "22.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.4",
                        "spread": "22.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "792"
                      },
                      {
                        "groupId": "OG001",
                        "value": "788"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.7",
                        "spread": "21.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.3",
                        "spread": "24.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "772"
                      },
                      {
                        "groupId": "OG001",
                        "value": "743"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.6",
                        "spread": "21.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.2",
                        "spread": "24.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "805"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.2",
                        "spread": "21.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.7",
                        "spread": "25.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "742"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.4",
                        "spread": "23.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.5",
                        "spread": "24.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "719"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.8",
                        "spread": "22.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.0",
                        "spread": "23.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Constipation",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "spread": "0.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "864"
                      },
                      {
                        "groupId": "OG001",
                        "value": "878"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.2",
                        "spread": "13.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.7",
                        "spread": "12.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "832"
                      },
                      {
                        "groupId": "OG001",
                        "value": "848"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.7",
                        "spread": "20.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.2",
                        "spread": "18.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "813"
                      },
                      {
                        "groupId": "OG001",
                        "value": "815"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "32.5",
                        "spread": "32.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "16.0",
                        "spread": "26.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "824"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28.4",
                        "spread": "30.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "11.3",
                        "spread": "23.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "810"
                      },
                      {
                        "groupId": "OG001",
                        "value": "824"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "26.5",
                        "spread": "30.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.3",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "815"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "23.9",
                        "spread": "30.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.8",
                        "spread": "22.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "788"
                      },
                      {
                        "groupId": "OG001",
                        "value": "786"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.6",
                        "spread": "24.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.7",
                        "spread": "21.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "767"
                      },
                      {
                        "groupId": "OG001",
                        "value": "740"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.5",
                        "spread": "26.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.1",
                        "spread": "20.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "798"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.3",
                        "spread": "25.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.0",
                        "spread": "19.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "759"
                      },
                      {
                        "groupId": "OG001",
                        "value": "734"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.3",
                        "spread": "16.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.1",
                        "spread": "16.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "732"
                      },
                      {
                        "groupId": "OG001",
                        "value": "712"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.3",
                        "spread": "17.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "spread": "17.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Diarrhea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "887"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.8",
                        "spread": "14.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.2",
                        "spread": "14.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "838"
                      },
                      {
                        "groupId": "OG001",
                        "value": "856"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.4",
                        "spread": "21.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.2",
                        "spread": "21.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "825"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "11.6",
                        "spread": "22.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.4",
                        "spread": "20.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "833"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13.4",
                        "spread": "23.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.5",
                        "spread": "20.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "833"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "14.3",
                        "spread": "23.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.9",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "826"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13.7",
                        "spread": "22.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.6",
                        "spread": "19.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "790"
                      },
                      {
                        "groupId": "OG001",
                        "value": "792"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.8",
                        "spread": "19.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.5",
                        "spread": "21.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "773"
                      },
                      {
                        "groupId": "OG001",
                        "value": "750"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.8",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.1",
                        "spread": "21.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "809"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.6",
                        "spread": "21.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.8",
                        "spread": "22.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "743"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.0",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.3",
                        "spread": "19.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "722"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.2",
                        "spread": "20.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.8",
                        "spread": "20.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Dyspnea",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "868"
                      },
                      {
                        "groupId": "OG001",
                        "value": "887"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "21.5",
                        "spread": "18.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "20.6",
                        "spread": "18.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "837"
                      },
                      {
                        "groupId": "OG001",
                        "value": "857"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13.2",
                        "spread": "21.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "14.4",
                        "spread": "22.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "815"
                      },
                      {
                        "groupId": "OG001",
                        "value": "825"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "15.4",
                        "spread": "22.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "11.2",
                        "spread": "21.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "833"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "15.3",
                        "spread": "23.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.7",
                        "spread": "20.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "834"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16.0",
                        "spread": "23.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.2",
                        "spread": "20.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "815"
                      },
                      {
                        "groupId": "OG001",
                        "value": "826"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "14.9",
                        "spread": "22.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.4",
                        "spread": "21.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "790"
                      },
                      {
                        "groupId": "OG001",
                        "value": "791"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.4",
                        "spread": "22.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.8",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "772"
                      },
                      {
                        "groupId": "OG001",
                        "value": "751"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.7",
                        "spread": "22.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.6",
                        "spread": "22.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "809"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.5",
                        "spread": "22.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.3",
                        "spread": "21.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "765"
                      },
                      {
                        "groupId": "OG001",
                        "value": "744"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.8",
                        "spread": "21.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.1",
                        "spread": "21.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "739"
                      },
                      {
                        "groupId": "OG001",
                        "value": "722"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.9",
                        "spread": "22.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.8",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Fatigue",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-5.6",
                        "spread": "39.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "859"
                      },
                      {
                        "groupId": "OG001",
                        "value": "876"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "20.1",
                        "spread": "28.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "19.9",
                        "spread": "28.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "825"
                      },
                      {
                        "groupId": "OG001",
                        "value": "843"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.2",
                        "spread": "25.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.3",
                        "spread": "24.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "810"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.0",
                        "spread": "25.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.6",
                        "spread": "25.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "810"
                      },
                      {
                        "groupId": "OG001",
                        "value": "820"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.9",
                        "spread": "24.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.4",
                        "spread": "25.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "802"
                      },
                      {
                        "groupId": "OG001",
                        "value": "820"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.7",
                        "spread": "24.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.2",
                        "spread": "25.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "801"
                      },
                      {
                        "groupId": "OG001",
                        "value": "811"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.4",
                        "spread": "25.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.7",
                        "spread": "26.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "784"
                      },
                      {
                        "groupId": "OG001",
                        "value": "782"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.9",
                        "spread": "25.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.5",
                        "spread": "26.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "763"
                      },
                      {
                        "groupId": "OG001",
                        "value": "736"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.4",
                        "spread": "25.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "spread": "27.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "799"
                      },
                      {
                        "groupId": "OG001",
                        "value": "797"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.1",
                        "spread": "27.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.7",
                        "spread": "25.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "755"
                      },
                      {
                        "groupId": "OG001",
                        "value": "732"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.8",
                        "spread": "27.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.2",
                        "spread": "28.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "728"
                      },
                      {
                        "groupId": "OG001",
                        "value": "708"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.1",
                        "spread": "28.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.8",
                        "spread": "28.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Financial Difficulties",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "spread": "0.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "888"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "23.9",
                        "spread": "26.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "24.9",
                        "spread": "27.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "838"
                      },
                      {
                        "groupId": "OG001",
                        "value": "857"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.6",
                        "spread": "30.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.8",
                        "spread": "28.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "828"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.0",
                        "spread": "30.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.4",
                        "spread": "30.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "815"
                      },
                      {
                        "groupId": "OG001",
                        "value": "835"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.2",
                        "spread": "30.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.1",
                        "spread": "30.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "835"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.6",
                        "spread": "31.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.1",
                        "spread": "30.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.2",
                        "spread": "31.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.1",
                        "spread": "29.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "790"
                      },
                      {
                        "groupId": "OG001",
                        "value": "791"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.3",
                        "spread": "30.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.1",
                        "spread": "29.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "773"
                      },
                      {
                        "groupId": "OG001",
                        "value": "751"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.7",
                        "spread": "30.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.7",
                        "spread": "30.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "807"
                      },
                      {
                        "groupId": "OG001",
                        "value": "810"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.5",
                        "spread": "30.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.9",
                        "spread": "30.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "765"
                      },
                      {
                        "groupId": "OG001",
                        "value": "744"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.9",
                        "spread": "29.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.3",
                        "spread": "29.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "739"
                      },
                      {
                        "groupId": "OG001",
                        "value": "724"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "spread": "30.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.9",
                        "spread": "30.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Insomnia",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "887"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.6",
                        "spread": "9.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.3",
                        "spread": "7.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "839"
                      },
                      {
                        "groupId": "OG001",
                        "value": "856"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.4",
                        "spread": "19.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.5",
                        "spread": "17.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.0",
                        "spread": "16.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.5",
                        "spread": "16.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "833"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.0",
                        "spread": "16.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.2",
                        "spread": "13.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "834"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.7",
                        "spread": "16.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.7",
                        "spread": "12.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "826"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.0",
                        "spread": "15.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.2",
                        "spread": "13.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "792"
                      },
                      {
                        "groupId": "OG001",
                        "value": "792"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.1",
                        "spread": "13.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.8",
                        "spread": "11.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "773"
                      },
                      {
                        "groupId": "OG001",
                        "value": "751"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.1",
                        "spread": "12.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.0",
                        "spread": "12.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "806"
                      },
                      {
                        "groupId": "OG001",
                        "value": "809"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.9",
                        "spread": "13.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.7",
                        "spread": "12.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "744"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.2",
                        "spread": "11.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.1",
                        "spread": "10.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "721"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.5",
                        "spread": "12.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.6",
                        "spread": "10.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Nausea/Vomiting",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-8.3",
                        "spread": "11.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "889"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "17.4",
                        "spread": "20.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "16.4",
                        "spread": "20.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "839"
                      },
                      {
                        "groupId": "OG001",
                        "value": "859"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.8",
                        "spread": "22.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.1",
                        "spread": "22.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "828"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.0",
                        "spread": "24.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.8",
                        "spread": "23.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "818"
                      },
                      {
                        "groupId": "OG001",
                        "value": "836"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.5",
                        "spread": "23.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.5",
                        "spread": "22.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "836"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.4",
                        "spread": "23.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.1",
                        "spread": "23.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "828"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.2",
                        "spread": "23.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.8",
                        "spread": "23.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "791"
                      },
                      {
                        "groupId": "OG001",
                        "value": "792"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.4",
                        "spread": "22.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.9",
                        "spread": "23.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "773"
                      },
                      {
                        "groupId": "OG001",
                        "value": "753"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.0",
                        "spread": "23.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.7",
                        "spread": "24.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "809"
                      },
                      {
                        "groupId": "OG001",
                        "value": "812"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.9",
                        "spread": "23.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.1",
                        "spread": "24.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "746"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.8",
                        "spread": "23.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.4",
                        "spread": "22.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "741"
                      },
                      {
                        "groupId": "OG001",
                        "value": "725"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "spread": "23.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.5",
                        "spread": "21.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Pain",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "-25.0",
                        "spread": "35.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "864"
                      },
                      {
                        "groupId": "OG001",
                        "value": "879"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "88.6",
                        "spread": "16.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "88.7",
                        "spread": "16.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "832"
                      },
                      {
                        "groupId": "OG001",
                        "value": "851"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.7",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.9",
                        "spread": "19.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "813"
                      },
                      {
                        "groupId": "OG001",
                        "value": "818"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.4",
                        "spread": "20.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.8",
                        "spread": "19.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "824"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.1",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.4",
                        "spread": "19.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "810"
                      },
                      {
                        "groupId": "OG001",
                        "value": "825"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.8",
                        "spread": "21.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.9",
                        "spread": "19.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "807"
                      },
                      {
                        "groupId": "OG001",
                        "value": "816"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.8",
                        "spread": "21.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-7.3",
                        "spread": "20.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "789"
                      },
                      {
                        "groupId": "OG001",
                        "value": "787"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.3",
                        "spread": "20.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-7.6",
                        "spread": "20.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "742"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.1",
                        "spread": "20.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-8.1",
                        "spread": "20.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "800"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.7",
                        "spread": "22.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-8.4",
                        "spread": "20.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "760"
                      },
                      {
                        "groupId": "OG001",
                        "value": "735"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.0",
                        "spread": "20.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.1",
                        "spread": "19.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "733"
                      },
                      {
                        "groupId": "OG001",
                        "value": "713"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-7.1",
                        "spread": "22.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.0",
                        "spread": "20.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Cognitive Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "864"
                      },
                      {
                        "groupId": "OG001",
                        "value": "880"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "76.0",
                        "spread": "19.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "75.7",
                        "spread": "20.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "832"
                      },
                      {
                        "groupId": "OG001",
                        "value": "849"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.1",
                        "spread": "20.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "spread": "19.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "813"
                      },
                      {
                        "groupId": "OG001",
                        "value": "819"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.6",
                        "spread": "19.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "825"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.9",
                        "spread": "21.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.2",
                        "spread": "19.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "810"
                      },
                      {
                        "groupId": "OG001",
                        "value": "826"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.5",
                        "spread": "22.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.8",
                        "spread": "20.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "817"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.2",
                        "spread": "22.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.6",
                        "spread": "21.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "789"
                      },
                      {
                        "groupId": "OG001",
                        "value": "788"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.1",
                        "spread": "20.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.9",
                        "spread": "21.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "743"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.1",
                        "spread": "21.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.5",
                        "spread": "21.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "806"
                      },
                      {
                        "groupId": "OG001",
                        "value": "801"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.0",
                        "spread": "22.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.1",
                        "spread": "21.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "760"
                      },
                      {
                        "groupId": "OG001",
                        "value": "736"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.7",
                        "spread": "21.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.1",
                        "spread": "21.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "733"
                      },
                      {
                        "groupId": "OG001",
                        "value": "714"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.8",
                        "spread": "22.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.5",
                        "spread": "21.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Emotional Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "12.5",
                        "spread": "17.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "889"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "88.4",
                        "spread": "13.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "89.1",
                        "spread": "12.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "838"
                      },
                      {
                        "groupId": "OG001",
                        "value": "859"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.0",
                        "spread": "14.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.9",
                        "spread": "13.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-7.8",
                        "spread": "15.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.8",
                        "spread": "12.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "835"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-7.1",
                        "spread": "15.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.1",
                        "spread": "13.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "835"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.4",
                        "spread": "16.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "13.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.3",
                        "spread": "16.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "13.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "789"
                      },
                      {
                        "groupId": "OG001",
                        "value": "793"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.0",
                        "spread": "15.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.8",
                        "spread": "14.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "773"
                      },
                      {
                        "groupId": "OG001",
                        "value": "752"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.7",
                        "spread": "14.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.2",
                        "spread": "14.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "810"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.2",
                        "spread": "14.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.9",
                        "spread": "15.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "747"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.6",
                        "spread": "14.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.6",
                        "spread": "13.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "739"
                      },
                      {
                        "groupId": "OG001",
                        "value": "724"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.1",
                        "spread": "15.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.8",
                        "spread": "13.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Physical Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "13.3",
                        "spread": "18.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "869"
                      },
                      {
                        "groupId": "OG001",
                        "value": "889"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "83.1",
                        "spread": "21.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83.4",
                        "spread": "21.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "837"
                      },
                      {
                        "groupId": "OG001",
                        "value": "859"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.1",
                        "spread": "24.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.7",
                        "spread": "24.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "816"
                      },
                      {
                        "groupId": "OG001",
                        "value": "828"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.7",
                        "spread": "26.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.5",
                        "spread": "24.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "835"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.9",
                        "spread": "26.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.7",
                        "spread": "23.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "815"
                      },
                      {
                        "groupId": "OG001",
                        "value": "836"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.7",
                        "spread": "27.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.2",
                        "spread": "23.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "817"
                      },
                      {
                        "groupId": "OG001",
                        "value": "827"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.4",
                        "spread": "27.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "23.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "792"
                      },
                      {
                        "groupId": "OG001",
                        "value": "792"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.3",
                        "spread": "25.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.2",
                        "spread": "24.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "772"
                      },
                      {
                        "groupId": "OG001",
                        "value": "752"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.5",
                        "spread": "25.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.3",
                        "spread": "25.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "806"
                      },
                      {
                        "groupId": "OG001",
                        "value": "811"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.2",
                        "spread": "26.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "24.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "746"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.2",
                        "spread": "24.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.4",
                        "spread": "24.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "724"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.6",
                        "spread": "25.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.7",
                        "spread": "23.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Role Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "8.3",
                        "spread": "11.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "863"
                      },
                      {
                        "groupId": "OG001",
                        "value": "877"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "83.0",
                        "spread": "22.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83.2",
                        "spread": "21.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "831"
                      },
                      {
                        "groupId": "OG001",
                        "value": "849"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.0",
                        "spread": "24.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.3",
                        "spread": "22.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "812"
                      },
                      {
                        "groupId": "OG001",
                        "value": "816"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.1",
                        "spread": "26.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.1",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "823"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.5",
                        "spread": "25.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.3",
                        "spread": "24.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "823"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.3",
                        "spread": "26.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.2",
                        "spread": "24.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "815"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.7",
                        "spread": "26.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.6",
                        "spread": "23.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "789"
                      },
                      {
                        "groupId": "OG001",
                        "value": "785"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.7",
                        "spread": "25.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.4",
                        "spread": "24.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "738"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.1",
                        "spread": "25.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.4",
                        "spread": "24.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "804"
                      },
                      {
                        "groupId": "OG001",
                        "value": "798"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.3",
                        "spread": "26.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.6",
                        "spread": "24.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "759"
                      },
                      {
                        "groupId": "OG001",
                        "value": "733"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.3",
                        "spread": "24.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.0",
                        "spread": "24.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "732"
                      },
                      {
                        "groupId": "OG001",
                        "value": "711"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.6",
                        "spread": "25.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.4",
                        "spread": "22.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Social Functioning",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "33.3",
                        "spread": "47.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "863"
                      },
                      {
                        "groupId": "OG001",
                        "value": "878"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "74.3",
                        "spread": "18.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "73.9",
                        "spread": "18.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "831"
                      },
                      {
                        "groupId": "OG001",
                        "value": "850"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-7.5",
                        "spread": "20.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-7.2",
                        "spread": "20.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "812"
                      },
                      {
                        "groupId": "OG001",
                        "value": "815"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-12.4",
                        "spread": "22.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-7.1",
                        "spread": "20.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "814"
                      },
                      {
                        "groupId": "OG001",
                        "value": "823"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.7",
                        "spread": "20.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.2",
                        "spread": "19.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "807"
                      },
                      {
                        "groupId": "OG001",
                        "value": "824"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-12.7",
                        "spread": "21.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.5",
                        "spread": "19.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "807"
                      },
                      {
                        "groupId": "OG001",
                        "value": "815"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-12.1",
                        "spread": "21.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.8",
                        "spread": "19.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "784"
                      },
                      {
                        "groupId": "OG001",
                        "value": "787"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.9",
                        "spread": "20.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.4",
                        "spread": "20.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "766"
                      },
                      {
                        "groupId": "OG001",
                        "value": "741"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.9",
                        "spread": "21.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.3",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "804"
                      },
                      {
                        "groupId": "OG001",
                        "value": "798"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.5",
                        "spread": "21.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.9",
                        "spread": "20.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "758"
                      },
                      {
                        "groupId": "OG001",
                        "value": "733"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.6",
                        "spread": "21.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.3",
                        "spread": "21.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "731"
                      },
                      {
                        "groupId": "OG001",
                        "value": "712"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.2",
                        "spread": "21.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.2",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Global Health Status",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG001",
                        "value": "16.7",
                        "spread": "23.6"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "EORTC Quality of Life Questionnaire-Breast Cancer 23 (QLQ-BR23) Score",
            "description": "EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30. There are four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \\[FP\\]) and four symptom scales (systemic side effects \\[SE\\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Higher scores for symptom scales represent higher levels of symptoms/problems. For functional scales, positive change from baseline indicated improvement in quality of life (QOL) while negative change from baseline indicated a deterioration. For symptom scales, positive change from baseline indicated deterioration and negative change indicated improvement.",
            "populationDescription": "The Patient Reported Outcome (PRO) Population includes participants with both a baseline assessment and at least one post-baseline assessment in any PRO items. The variation of the number of participants in the table reflects the number of participants with corresponding scores at the given visits and at baseline.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Units on a Scale",
            "timeFrame": "Baseline, Cycles 1, 2, 3, 4, 5, 9, 14, End of Treatment, Follow-up Month 6, Follow-up Month 12, Follow-up Month 18",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "869"
                  },
                  {
                    "groupId": "OG001",
                    "value": "891"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "844"
                      },
                      {
                        "groupId": "OG001",
                        "value": "861"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "19.9",
                        "spread": "18.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "19.5",
                        "spread": "18.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "804"
                      },
                      {
                        "groupId": "OG001",
                        "value": "831"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.3",
                        "spread": "19.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.1",
                        "spread": "18.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "788"
                      },
                      {
                        "groupId": "OG001",
                        "value": "798"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.8",
                        "spread": "18.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.0",
                        "spread": "18.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "788"
                      },
                      {
                        "groupId": "OG001",
                        "value": "805"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.5",
                        "spread": "18.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "18.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "786"
                      },
                      {
                        "groupId": "OG001",
                        "value": "803"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "spread": "19.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.9",
                        "spread": "19.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "790"
                      },
                      {
                        "groupId": "OG001",
                        "value": "798"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.5",
                        "spread": "20.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.6",
                        "spread": "19.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "765"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.2",
                        "spread": "20.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.1",
                        "spread": "19.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "754"
                      },
                      {
                        "groupId": "OG001",
                        "value": "725"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.3",
                        "spread": "21.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1.3",
                        "spread": "21.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "784"
                      },
                      {
                        "groupId": "OG001",
                        "value": "785"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.1",
                        "spread": "21.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.4",
                        "spread": "21.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "739"
                      },
                      {
                        "groupId": "OG001",
                        "value": "716"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.1",
                        "spread": "22.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.3",
                        "spread": "20.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "714"
                      },
                      {
                        "groupId": "OG001",
                        "value": "693"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.8",
                        "spread": "22.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.8",
                        "spread": "20.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Arm Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "843"
                      },
                      {
                        "groupId": "OG001",
                        "value": "859"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "17.5",
                        "spread": "17.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "16.8",
                        "spread": "16.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "802"
                      },
                      {
                        "groupId": "OG001",
                        "value": "828"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.3",
                        "spread": "16.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.5",
                        "spread": "16.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "786"
                      },
                      {
                        "groupId": "OG001",
                        "value": "795"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.3",
                        "spread": "17.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.9",
                        "spread": "16.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "785"
                      },
                      {
                        "groupId": "OG001",
                        "value": "803"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.0",
                        "spread": "17.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.1",
                        "spread": "16.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "786"
                      },
                      {
                        "groupId": "OG001",
                        "value": "800"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.9",
                        "spread": "17.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.3",
                        "spread": "17.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "787"
                      },
                      {
                        "groupId": "OG001",
                        "value": "796"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.1",
                        "spread": "18.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.6",
                        "spread": "18.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "763"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.7",
                        "spread": "19.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.3",
                        "spread": "17.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "751"
                      },
                      {
                        "groupId": "OG001",
                        "value": "724"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.2",
                        "spread": "18.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.5",
                        "spread": "19.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "781"
                      },
                      {
                        "groupId": "OG001",
                        "value": "783"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "spread": "19.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.3",
                        "spread": "18.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "738"
                      },
                      {
                        "groupId": "OG001",
                        "value": "714"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.5",
                        "spread": "19.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.5",
                        "spread": "18.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "713"
                      },
                      {
                        "groupId": "OG001",
                        "value": "691"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.2",
                        "spread": "18.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.7",
                        "spread": "18.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Breast Symptoms",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Systemic Therapy Side Effects (SE)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "845"
                      },
                      {
                        "groupId": "OG001",
                        "value": "868"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.5",
                        "spread": "9.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.7",
                        "spread": "9.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "812"
                      },
                      {
                        "groupId": "OG001",
                        "value": "838"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "24.9",
                        "spread": "17.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "23.3",
                        "spread": "17.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "791"
                      },
                      {
                        "groupId": "OG001",
                        "value": "805"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "24.1",
                        "spread": "18.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "18.3",
                        "spread": "16.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "793"
                      },
                      {
                        "groupId": "OG001",
                        "value": "812"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "23.4",
                        "spread": "17.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "15.1",
                        "spread": "15.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "793"
                      },
                      {
                        "groupId": "OG001",
                        "value": "814"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "23.1",
                        "spread": "18.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13.2",
                        "spread": "15.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "793"
                      },
                      {
                        "groupId": "OG001",
                        "value": "806"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "20.0",
                        "spread": "17.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "11.8",
                        "spread": "14.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "772"
                      },
                      {
                        "groupId": "OG001",
                        "value": "770"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9.5",
                        "spread": "13.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.4",
                        "spread": "14.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "755"
                      },
                      {
                        "groupId": "OG001",
                        "value": "730"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.5",
                        "spread": "12.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.8",
                        "spread": "13.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "785"
                      },
                      {
                        "groupId": "OG001",
                        "value": "793"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "7.2",
                        "spread": "13.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.5",
                        "spread": "13.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "745"
                      },
                      {
                        "groupId": "OG001",
                        "value": "726"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.8",
                        "spread": "12.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.2",
                        "spread": "12.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "716"
                      },
                      {
                        "groupId": "OG001",
                        "value": "705"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.4",
                        "spread": "12.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4.2",
                        "spread": "13.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Systemic Therapy SE",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "205"
                      },
                      {
                        "groupId": "OG001",
                        "value": "213"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "13.2",
                        "spread": "23.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "14.2",
                        "spread": "22.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "169"
                      },
                      {
                        "groupId": "OG001",
                        "value": "168"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "35.1",
                        "spread": "37.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "25.2",
                        "spread": "35.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "152"
                      },
                      {
                        "groupId": "OG001",
                        "value": "130"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28.7",
                        "spread": "36.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "21.8",
                        "spread": "36.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "132"
                      },
                      {
                        "groupId": "OG001",
                        "value": "98"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28.8",
                        "spread": "36.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "21.4",
                        "spread": "38.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "136"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28.4",
                        "spread": "37.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "19.7",
                        "spread": "34.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "130"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "26.4",
                        "spread": "36.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "10.0",
                        "spread": "36.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "85"
                      },
                      {
                        "groupId": "OG001",
                        "value": "72"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "11.8",
                        "spread": "33.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.0",
                        "spread": "36.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "68"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9.3",
                        "spread": "32.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.5",
                        "spread": "26.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "75"
                      },
                      {
                        "groupId": "OG001",
                        "value": "63"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "17.3",
                        "spread": "33.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "spread": "28.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "86"
                      },
                      {
                        "groupId": "OG001",
                        "value": "67"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6.2",
                        "spread": "26.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "21.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "84"
                      },
                      {
                        "groupId": "OG001",
                        "value": "71"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.4",
                        "spread": "28.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.8",
                        "spread": "29.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Upset by Hair Loss Item",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "841"
                      },
                      {
                        "groupId": "OG001",
                        "value": "867"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "78.5",
                        "spread": "23.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "78.9",
                        "spread": "24.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "808"
                      },
                      {
                        "groupId": "OG001",
                        "value": "834"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-13.7",
                        "spread": "23.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-13.3",
                        "spread": "23.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "788"
                      },
                      {
                        "groupId": "OG001",
                        "value": "801"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-12.7",
                        "spread": "23.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-10.1",
                        "spread": "23.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "787"
                      },
                      {
                        "groupId": "OG001",
                        "value": "807"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.5",
                        "spread": "24.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.6",
                        "spread": "22.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "788"
                      },
                      {
                        "groupId": "OG001",
                        "value": "810"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.4",
                        "spread": "24.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.9",
                        "spread": "23.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "790"
                      },
                      {
                        "groupId": "OG001",
                        "value": "802"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.5",
                        "spread": "24.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-5.0",
                        "spread": "22.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "768"
                      },
                      {
                        "groupId": "OG001",
                        "value": "766"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.9",
                        "spread": "22.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.2",
                        "spread": "21.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "750"
                      },
                      {
                        "groupId": "OG001",
                        "value": "726"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.5",
                        "spread": "23.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.4",
                        "spread": "23.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "783"
                      },
                      {
                        "groupId": "OG001",
                        "value": "785"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.3",
                        "spread": "23.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.9",
                        "spread": "22.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "720"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.3",
                        "spread": "23.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.3",
                        "spread": "23.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "712"
                      },
                      {
                        "groupId": "OG001",
                        "value": "703"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "spread": "24.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.7",
                        "spread": "23.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Body Image",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Future Perspectives (FP)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "842"
                      },
                      {
                        "groupId": "OG001",
                        "value": "868"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "49.3",
                        "spread": "31.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "49.8",
                        "spread": "30.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "805"
                      },
                      {
                        "groupId": "OG001",
                        "value": "836"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.3",
                        "spread": "30.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.3",
                        "spread": "31.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "786"
                      },
                      {
                        "groupId": "OG001",
                        "value": "803"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.4",
                        "spread": "31.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.7",
                        "spread": "30.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "786"
                      },
                      {
                        "groupId": "OG001",
                        "value": "811"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.2",
                        "spread": "32.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.5",
                        "spread": "30.1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "787"
                      },
                      {
                        "groupId": "OG001",
                        "value": "814"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.2",
                        "spread": "31.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.8",
                        "spread": "30.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "787"
                      },
                      {
                        "groupId": "OG001",
                        "value": "804"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.9",
                        "spread": "32.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.7",
                        "spread": "30.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "762"
                      },
                      {
                        "groupId": "OG001",
                        "value": "767"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.2",
                        "spread": "32.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.4",
                        "spread": "31.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "752"
                      },
                      {
                        "groupId": "OG001",
                        "value": "726"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9.5",
                        "spread": "32.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.9",
                        "spread": "33.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "782"
                      },
                      {
                        "groupId": "OG001",
                        "value": "787"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "8.5",
                        "spread": "32.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7.6",
                        "spread": "32.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "740"
                      },
                      {
                        "groupId": "OG001",
                        "value": "720"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.5",
                        "spread": "31.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "12.6",
                        "spread": "32.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "711"
                      },
                      {
                        "groupId": "OG001",
                        "value": "703"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "15.0",
                        "spread": "34.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13.1",
                        "spread": "33.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: FP",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "369"
                      },
                      {
                        "groupId": "OG001",
                        "value": "380"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "43.4",
                        "spread": "32.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "46.7",
                        "spread": "34.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "233"
                      },
                      {
                        "groupId": "OG001",
                        "value": "260"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.9",
                        "spread": "26.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-8.2",
                        "spread": "27.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "196"
                      },
                      {
                        "groupId": "OG001",
                        "value": "227"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.5",
                        "spread": "30.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-10.7",
                        "spread": "29.2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "205"
                      },
                      {
                        "groupId": "OG001",
                        "value": "235"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.4",
                        "spread": "26.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-8.9",
                        "spread": "31.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "190"
                      },
                      {
                        "groupId": "OG001",
                        "value": "228"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.9",
                        "spread": "30.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-9.2",
                        "spread": "28.3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "204"
                      },
                      {
                        "groupId": "OG001",
                        "value": "224"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-14.2",
                        "spread": "28.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-8.8",
                        "spread": "30.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "221"
                      },
                      {
                        "groupId": "OG001",
                        "value": "220"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.4",
                        "spread": "29.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-7.4",
                        "spread": "30.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "203"
                      },
                      {
                        "groupId": "OG001",
                        "value": "213"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.9",
                        "spread": "28.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-9.7",
                        "spread": "31.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "224"
                      },
                      {
                        "groupId": "OG001",
                        "value": "236"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.5",
                        "spread": "29.2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-9.7",
                        "spread": "29.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "212"
                      },
                      {
                        "groupId": "OG001",
                        "value": "223"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.6",
                        "spread": "28.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.0",
                        "spread": "30.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "212"
                      },
                      {
                        "groupId": "OG001",
                        "value": "204"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.7",
                        "spread": "30.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.3",
                        "spread": "31.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Sexual Enjoyment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "819"
                      },
                      {
                        "groupId": "OG001",
                        "value": "829"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16.7",
                        "spread": "22.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "18.3",
                        "spread": "22.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 1: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "757"
                      },
                      {
                        "groupId": "OG001",
                        "value": "779"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.3",
                        "spread": "18.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.5",
                        "spread": "18.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 2: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "728"
                      },
                      {
                        "groupId": "OG001",
                        "value": "745"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.8",
                        "spread": "19.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.4",
                        "spread": "18.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 3: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "734"
                      },
                      {
                        "groupId": "OG001",
                        "value": "740"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.6",
                        "spread": "19.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.3",
                        "spread": "19.0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 4: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "726"
                      },
                      {
                        "groupId": "OG001",
                        "value": "743"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.8",
                        "spread": "19.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.4",
                        "spread": "17.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 5: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "730"
                      },
                      {
                        "groupId": "OG001",
                        "value": "738"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.9",
                        "spread": "19.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.0",
                        "spread": "19.5"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 9: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "710"
                      },
                      {
                        "groupId": "OG001",
                        "value": "704"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.4",
                        "spread": "19.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.8",
                        "spread": "20.8"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at Cycle 14: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "696"
                      },
                      {
                        "groupId": "OG001",
                        "value": "671"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.8",
                        "spread": "20.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.8",
                        "spread": "20.6"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at EoT: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "716"
                      },
                      {
                        "groupId": "OG001",
                        "value": "724"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.5",
                        "spread": "20.9"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.7",
                        "spread": "19.7"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 6: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "675"
                      },
                      {
                        "groupId": "OG001",
                        "value": "658"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.6",
                        "spread": "22.6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.6",
                        "spread": "20.4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 12: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "651"
                      },
                      {
                        "groupId": "OG001",
                        "value": "639"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.9",
                        "spread": "21.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.9",
                        "spread": "20.9"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Change at FU Month 18: Sexual Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to Clinically Meaningful Deterioration in the Global Health Status/ Quality of Life and Functional (Physical, Role, and Cognitive) Subscales of the QLQ-C30 From First HER2-Targeted Treatment",
            "description": "The time to clinically meaningful deterioration in the global health status/Quality of life and Functional (Physical, Role, and Cognitive) subscales of the the QLQ-C30 was assessed from the time of the HER2-Targeted treatment to the worsening in the respective scales. Clinically meaningful deterioration is defined as a decrease in score of 10 points in Physical functioning and HRQoL; decrease of 7 points in Cognitive functioning, and decrease of 14 points in Role functioning.",
            "populationDescription": "The Patient Reported Outcome (PRO) Population includes participants with both a baseline assessment and at least one post-baseline assessment in any PRO items. This subset population includes only participants who received HER2-targeted therapy.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "months",
            "timeFrame": "From start of HER-2 targeted treatment up to 18 months after treatment discontinuation. The median time to clinically meaningful deterioration was assessed based on the data collection described above.",
            "groups": [
              {
                "id": "OG000",
                "title": "Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane",
                "description": "Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              },
              {
                "id": "OG001",
                "title": "Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab",
                "description": "Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \\[1 Cycle = 21 days\\]) following anthracycline \\[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\\] based chemotherapy."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "864"
                  },
                  {
                    "groupId": "OG001",
                    "value": "884"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "GHS/QoL Score",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "858"
                      },
                      {
                        "groupId": "OG001",
                        "value": "879"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.73",
                        "lowerLimit": "2.10",
                        "upperLimit": "2.83"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13.57",
                        "lowerLimit": "9.20",
                        "upperLimit": "21.91"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Physical Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "861"
                      },
                      {
                        "groupId": "OG001",
                        "value": "879"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "25.53",
                        "lowerLimit": "13.34",
                        "upperLimit": "NA",
                        "comment": "Upper limit not reached."
                      },
                      {
                        "groupId": "OG001",
                        "value": "NA",
                        "lowerLimit": "27.43",
                        "upperLimit": "NA",
                        "comment": "The median and upper limit were not reached."
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Role Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "859"
                      },
                      {
                        "groupId": "OG001",
                        "value": "880"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.23",
                        "lowerLimit": "2.10",
                        "upperLimit": "2.79"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.92",
                        "lowerLimit": "9.00",
                        "upperLimit": "14.36"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Cognitive Function",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "858"
                      },
                      {
                        "groupId": "OG001",
                        "value": "879"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.49",
                        "lowerLimit": "2.79",
                        "upperLimit": "5.82"
                      },
                      {
                        "groupId": "OG001",
                        "value": "9.46",
                        "lowerLimit": "8.57",
                        "upperLimit": "12.91"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02366793",
        "briefTitle": "Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.",
        "officialTitle": "Accessory Joint and Neural Mobilizations in Shoulder Range of Motion Restriction After Breast Cancer Surgery. A Pilot Randomized Clinical Trial."
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2013-09"
        },
        "completionDateStruct": {
          "date": "2014-06"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "University of Alcala"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 18,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {}
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02662621",
        "briefTitle": "Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors",
        "officialTitle": "Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for Early Diagnosis of Malgnant Solid Tumors"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2015-12-15"
        },
        "completionDateStruct": {
          "date": "2019-04-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Centre Georges Francois Leclerc"
        },
        "collaborators": [
          {
            "name": "INSERM U866 Facult\u00e9 de M\u00e9decine et Pharmacie"
          }
        ]
      },
      "conditionsModule": {
        "conditions": [
          "Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 71,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "France"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04389216",
        "briefTitle": "Radiofrequency Ablation (RFA) in Breast Tumors",
        "officialTitle": "Radiofrequency Ablation in Breast Tumors in Early Stages"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2020-05-01"
        },
        "completionDateStruct": {
          "date": "2025-09-09"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Hospital Universitari de Bellvitge"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Cancer Female"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "NA"
        ],
        "enrollmentInfo": {
          "count": 30,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "Spain"
          },
          {
            "country": "Spain"
          }
        ]
      }
    }
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00174434",
        "briefTitle": "Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer",
        "officialTitle": "A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting"
      },
      "statusModule": {
        "overallStatus": "COMPLETED",
        "startDateStruct": {
          "date": "2005-09"
        },
        "completionDateStruct": {
          "date": "2007-08"
        }
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Pfizer"
        }
      },
      "conditionsModule": {
        "conditions": [
          "Breast Neoplasms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE1"
        ],
        "enrollmentInfo": {
          "count": 22,
          "type": "ACTUAL"
        }
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          },
          {
            "country": "United States"
          }
        ]
      }
    }
  }
]